The URL can be used to link to this page

Home My WebLink About2020-09-22 Select Board PacketDowntown Parking Potential System Modifications Overview for Select Board January 21, 2020 Updated February 4, 2020 August 11, 2020 September 22, 2020 Cross -Disciplinary Team (PTTTF: Parking Traffic Transportation Task Force) •Management –Bob LeLacheur, Jean Delios •Planning / Economic Development –Julie Mercier, Erin Schaeffer, Andrew MacNichol •DPW / Engineering –Jane Kinsella, Chris Cole, Ryan Percival •Public Safety –PD: David Clark, Christine Amendola, Michael Scouten –FD: Paul Jackson Sources •Maps & Data: Downtown Reading Parking Study – 2018 Assessment, prepared by Nelson\Nygaard Consulting Associates, Inc.; 2019 Parking Survey •Anecdotal Information: Stakeholder feedback at public meetings; conversations with Police Dept. •Philosophy & Opportunities: based on industry practice and recommendations of Nelson\Nygaard 2018 Assessment Tonight’s Presentation •Systemwide Modifications –Brief Overview of Proposal No changes to Resident-Only areas or Resident Access Permit at this time •Outreach & Feedback •PTTTF Request of Select Board –VOTE ! 1)Leased Spaces 2)Employee Permit Program 3)Public Access 4)Kiosks in Public Lots & Kiosk Considerations •Supporting Documentation –Implementation Timeline –Engineering Field Inventory of Parking Spaces –Police/DPW Lighting Needs Assessment –Harnden Yard Lot Proposal –Map of Downtown Geographies Matt Smith of Nelson Nygaard is here! Systemwide Modifications [Brief Overview] Geography INNER CORE (orange) OUTER CORE (pink) User / Component Pros Considerations [SCENARIO based on STATED PHILOSOPHY] Makes sense for all-day users to park further out. Anyone who wants to park closer can pay in lot. Town assessing lighting and sidewalk upgrades, will need to decide whether to stripe spaces or just add signage to newly regulated areas. Eliminates single user spaces & 'adds' supply to system. Removes 'privatization of public spaces'. LEASING EMPLOYEES RESIDENTS COMMUTERS (1) Redistribute Employee Parking to Outer Core / (2) Expand Areas where Employees can park / (3) Increase # of Employee Permits available / (4) Cap at 5 per business for first month / (5) Offer first 5 Employee Permits per business for FREE, then charge $20/month for up to 10 additional permits per business on case-by-case basis Abolish Program & Re-allocate spaces: High Street (41) = "Public 2 Hr or All Day with Employee Permit" / Brande Court (4) = "Public 2 Hr", potential EV charging spaces / Harnden Yard/Union (13) = varied regs No changes to Resident-Only areas, Resident Access Permit, or commuter lots/access proposed at this time. Further study needed. No changes to Resident-Only areas, Resident Access Permit, or commuter lots/access proposed at this time. Further study needed. Changes Defined as: Area bounded by Woburn/Main/High* Defined as: Streets emanating 1-2 blocks outward from Inner Core** Proposal: "Public 2 Hr" or "Public 30 Min" on-street expanded where possible (i.e., Ash); "Employee Permit" areas on Gould, Green & Brande Ct Lot removed from Inner Core; Payment Kiosks added to Upper Haven & Brande Ct Lots; "No Parking" areas will remain; No changes to Resident-Only areas or Resident Access Permit Proposal: "Public 2 Hr or All Day with Employee Permit" on-street expanded where possible, including formalized spaces east of Main on Green & Bolton, and north of Woburn on Linden & Sanborn; "No Parking" areas will remain; No changes to Resident- Only areas or Resident Access Permit PUBLIC Provides more spaces for short-term users & empowers longer-term users to pay-to-stay. Cost escalation will disincentivize employees from parking in lot all day. (1) "Public 2 HR" or "Public 30 Min" on-street expanded where possible in Inner Core / (2) Kiosks put in Upper Haven & Brande Court Lots - no time limit, but cost escalation after 4 hours^ Need to discuss timeframe for regulations. On-street is currently 8:00AM- 5:00PM. Lots could be longer: 8:00AM - 6:00PM. *INNER CORE: EOP south on Woburn (not including any spaces on Woburn); north side of High (including spaces on north side of High only, not including spaces along train tracks); east side of Main (including spaces on both sides of Main) **OUTER CORE: 41 formerly leased spaces on High; Woburn, portion of Chute, Linden, Sanborn, Lowell by TH & church, Pleasant, Haven, Chapin, Green, Bolton, Goodall Sanford ^Price competitively to dissuade commuters & employees from parking all day Outreach & Feedback Outreach •We gathered a lot of feedback from businesses & residents: –Staff attended Chamber event at Tin Bucket –2/25 –Staff reviewed all correspondence –ongoing –Staff followed up with PDA Dental at their office –3/10 –Staff had Zoom session with PDA Dental –8/31 –Staff held 10 Zoom info/feedback sessions in August & September to gather feedback prior to 9/22 •Feedback from the Zoom sessions is summarized below Feedback (residents) •Resident concerns –Concerns about new mixed-use projects and parking supply –Safety issues w/lighting, sidewalks & plowing need to be addressed –Not enough commuter parking downtown (pre-COVID times) •Residents –other comments –Relief that we are not changing Resident Only areas at this time –Snow removal policy needed,could incentivize others to help –Consider angled parking on Haven Street –Long-term solution for contractor parking needed –More enforcement needed –Consider nearby parking demand/supply and trends –Reimagine CVS lot, and Reading, as an attraction &destination Feedback (businesses) •Business concerns –30 minutes free may not be enough in Brande Court Lot –Validation flexibility will be very important –Kiosks may be hard for elderly patrons to navigate –Paid parking may result in leakage –Safety issues w/lighting, sidewalks & plowing need to be addressed –No concerns expressed about abolishing the leasing program •Businesses –other comments –Changes to employee permit program sound reasonable –RNR Chamber offered to partner w/PD on safety training –More enforcement needed PTTTF Request of Select Board: Please VOTE! (1) Leased Spaces •Proposal: Abolish 58 leased spaces and add them back into the public supply, as follows: –High Street (41 spaces): “Public 2 Hour or All Day with Employee Permit” –Brande Court (4 spaces): “Public 2 Hour” –Harnden Yard Lot (13 spaces): •Spaces on northern and southeastern ends of lot: “Public 2 Hour or All Day with Employee Permit” •Spaces in center: “Public 2 Hour” as they are now •Spaces on eastern side of lot: “Police Business Only” •Tandem spaces: restriped as single spaces, “Police Business Only” (2) Employee Permit Program •Proposal: –Expand locations for Employee Permit parking in Outer Core •Formalize ~180 additional spaces for Employee Permit parking on streets north of Woburn Street and east of Main Street •Formalization via signage; striping potential in future if needed •Timeframe for Regulations: 8:00AM –5:00PM Mon-Fri (same as today) –Redistribute Employee Permit parking from Inner Core to Outer Core •Spaces on Gould Street, Green Street, Brande Court Lot Outer Core –Increase # of permits available from 145 to over 300 –Allow greater business participation by establishing a cap on permits per business, as follows: •Up to 5 FREE permits per business for first month of program •After first month, up to 10 additional permits per business for purchase, on case- by-case basis •Purchase price same as today: $240/year (3) Public Access •Proposal:Expand Public Access in Inner & Outer Cores –Inner Core: Add “Public 2 Hour” spaces •Unregulated portion of Ash Street is an opportunity –Outer Core: Expand areas for “Public 2 Hour” parking •Formalize ~180 additional spaces (same as spaces for Employee Permit parking) on streets north of Woburn Street and east of Main Street •Formalization via signage; striping potential in future if needed •Timeframe for Regulations: 8:00AM –5:00PM Mon-Fri (same as today) –Allow people to stay longer than 2 hours,if desired, by adding Paid Parking Kiosks with no time limit in Public Lots… (4) Kiosks in Public Lots •Proposal: –Install 2 multi-space paid parking kiosks each in Upper Haven Lot and Brande Court Lot (total of 4 kiosks) •Timeframe for Regulations: 8:00AM –6:00PM Mon-Fri •Time Limit: none •Pricing Scheme: 30 minutes free; $1/hour up to 4 hours; $2/hour after 4 hours –NB: 30 minute free period only available to people who stay 30 minutes or less •Kiosk Type: Pay-By-Plate, programmable by Parking App •Customer Accommodations: grace period, validation, etc. –Why Pay -By -Plate? •User-friendly: requires interface with kiosk one time •Easy to program into Mobile Parking App •Low maintenance •Yields the best utilization data, without compromising personal data •Parking Pass programs can allow discounts for certain registered plates •Higher revenue: each car plugs in plate which precludes piggy-backing on costs Kiosk Considerations •Kiosk Purchase Price: MAPC-negotiated lower rates; maximum $15k cost per kiosk (including all features & installation) •Ongoing Costs:Monthly wireless or electric bill; maintenance contract w/vendor or 3rd party; monthly service fee for Mobile Parking App •Leasing vs Purchasing: Can cost more to lease in long-run; leasing only recommended if Town uncertain which vendor to choose •Solar-Powered vs Hard-Wired: Staff will consider both options; elec. available •Screen Size: Big, readable, no glare, multi-lingual •Payment Options: Important for kiosk to accept cash, change, credit, App •Mobile Parking Apps: Continuity with nearby towns and MBTA important; can manage all parking permit programs for Town if desired •Validation: Parking Apps allow businesses to customize validation; business shares cost with customer •Passes: Town can consider different passes (Monthly, Contractor, Senior) •Enforcement:Kiosks make enforcement much easier, no new tech required •Management/Administration: Part -time staff role (programming, collection) Thank You Supporting Documentation Implementation Timeline *Select Board and Town Meeting votes likely needed; Staff confirming process with Town Counsel. September October November December January 1, 2021 Select Board VOTE VOTE Employee Permits - ordering & notification to businesses 200+ Regulatory Signs - ordering, fabrication & installation Education/Outreach Launch Modifications to Employee Permit Program & On-Street Regulations LAUNCH DATE! Kiosks Selection Process: Vetting vendors, interviews w/other Towns, etc. Administration/Contracts: Maintenance, collection, customer service Parking App Selection Process: Vetting vendors, contract terms Implementation: Funding, procurement, delivery & installation Downtown Parking - Systemwide Modifications - Implementation Timeline (8 week minimum; 12 weeks preferred) (6 week min; 8 weeks pref) Plan for Rollout in spring/summer 2021 (the longer the better, will extend into January and beyond as needed) Sept.-Jan.Feb.March April 2021 Jan 2022 Spring 2022 Prepare Capital Plan for sidewalks, lighting, etc. Establish Parking Benefit District* - organizational structure, legislation Town Meeting Gather data on Resident-Only areas & Commuter parking Survey Commuters & conduct Utilization Analysis Survey Downtown Stakeholders on 1st year of Modifications PTTTF report back to Select Board Downtown Parking - Systemwide Modifications - Other Components Town Clerk fax: 781-942-9070 781-942-9050 website: www.readingma.gov Application for Appointment to Boards, Committees and Commissions Name: Date: (Last) (First) (Middle) Address: Phone (Home): Phone (Work): Phone (Cell): Which number should be listed? Occupation: Number of years in Reading: E-mail address: Place a number next to your preferred position(s) (up to four choices) with number 1 being your first priority. (Please attach a resume if available) ___ Animal Control Appeals Committee ___ Audit Committee ___ Board of Assessors ___ Board of Cemetery Trustees ___ Board of Health ___ Board of Registrars ___ Bylaw Committee ___ Celebration Trust Committee ___ Climate Advisory Committee ___ Commissioners of Trust Funds ___ Community Planning and Development Commission ___ Conservation Commission ___ Constables ___ Council on Aging ___ Cultural Council ___ Custodian of Soldier and Sailor Graves ___ Finance Committee ___ Historic District Commission ___ Historical Commission ___ Housing Authority ___ Human Relations Advisory Committee ___ Permanent Building Committee ___ RCTV Board of Directors ___ Recreation Committee ___ Retirement Board ___ RMLD Citizen Advisory Board ___ Town Forest Committee ___ Trails Committee ___ Veterans Memorial Trust Fund Committee ___ Zoning Board of Appeals ___ Other Please outline relevant experience for the position(s) sought: Town of Reading 16 Lowell Street Reading MA 01867 Hartman Cynthia B 9-3-20 20C Carnation Circle, Reading, MA 01867 781-872-1619 617-241-8332 617-285-4033 home attorney 2 chartman16@comcast.net 1 many cases involving construction and real estate issues such as variances, easements, adverse possession claims, property line disputes, etc. I am familiar with many of the issues brought before the ZBA, and am used to investigating the facts and making a decision based on the applicable law. I have served on many Boards over the years, largely in the arts, and am currently on the Board of the Greenhouse Acres Condominium. Attorney since 1991, presently with MPD Law in Woburn. Specialty is civil litigation with an emphasis on real estate and business litigation. I have had Town Clerk fax: 781-942-9070 781-942-9050 website: www.readingma.gov Application for Appointment to Boards, Committees and Commissions Name: Date: (Last) (First) (Middle) Address: Phone (Home): Phone (Work): Phone (Cell): Which number should be listed? Occupation: Number of years in Reading: E-mail address: Place a number next to your preferred position(s) (up to four choices) with number 1 being your first priority. (Please attach a resume if available) ___ Animal Control Appeals Committee ___ Audit Committee ___ Board of Assessors ___ Board of Cemetery Trustees ___ Board of Health ___ Board of Registrars ___ Bylaw Committee ___ Celebration Trust Committee ___ Climate Advisory Committee ___ Commissioners of Trust Funds ___ Community Planning and Development Commission ___ Conservation Commission ___ Constables ___ Council on Aging ___ Cultural Council ___ Custodian of Soldier and Sailor Graves ___ Finance Committee ___ Historic District Commission ___ Historical Commission ___ Housing Authority ___ Human Relations Advisory Committee ___ Permanent Building Committee ___ RCTV Board of Directors ___ Recreation Committee ___ Retirement Board ___ RMLD Citizen Advisory Board ___ Town Forest Committee ___ Trails Committee ___ Veterans Memorial Trust Fund Committee ___ Zoning Board of Appeals ___ Other Please outline relevant experience for the position(s) sought: Town of Reading 16 Lowell Street Reading MA 01867 1 Harvard Medical School/Harvard School of Dental Medicine Date Prepared: 7/31/19 Name: Brian Healy Office Address: 60 Fenwood Rd, 09002O, Boston, MA 02115 Home Address: 62 Orange Street, Reading, MA 01867 Work Phone: 617-732-5376 Work Email: bchealy@partners.org Work FAX: 617-724-9878 Place of Birth: Freehold, NJ Education 2000 ScB Chemical engineering Brown University 2006 AM Biostatistics Harvard University 2007 PhD Biostatistics (Victor DeGruttola) Harvard University Postdoctoral Training 11/27/06- 11/26/07 Postdoctoral Fellow Neurology Brigham and Women’s Hospital Faculty Academic Appointments 11/07-05/11 Instructor Neurology Harvard Medical School 07/09- Instructor Biostatistics Harvard School of Public Health 05/11-11/19 Assistant Professor Neurology Harvard Medical School 05/14-11/19 Assistant Professor Biostatistics Harvard School of Public Health 11/19- Associate Professor Neurology Harvard Medical School 11/19- Associate Professor Biostatistics Harvard School of Public Health Appointments at Hospitals/Affiliated Institutions 11/26/07- Research Associate Neurology Massachusetts General Hospital 11/26/07- Research Associate Neurology Brigham and Women’s Hospital 01/08-12/08 Visiting Scientist Broad Institute 2 Other Professional Positions 09/00-06/02 Mathematics Teacher Intermediate School 125x, Bronx NY Major Administrative Leadership Positions Local 2009-2011 Course director-Introduction to Biostatistics for Basic Scientists Massachusetts General Hospital 2011- Course director-Harvard Catalyst Certificate in Applied Biostatistics Harvard Medical School 2016-2020 Co -course director-Masters of Medical Science and Clinical Investigation Harvard Medical School 2016-2020 Director of Clinical Research Methods Harvard Medical School Global and Continuing Education Professional Societies 2006- American Statistical Association 2009- American Academy of Neurology Grant Review Activities 2010 Ad hoc reviewer National Multiple Sclerosis Society 2010 Ad hoc reviewer Multiple Sclerosis Society of the United Kingdom 2011, 2013 Ad hoc reviewer Multiple Sclerosis Society of Canada 2018 Ad hoc reviewer Swiss National Science Foundation Editorial Activities Ad hoc Reviewer American Journal of Neuroradiology Annals of Epidemiology Annals of Neurology Circulation Clinical Trials Contemporary Clinical Trials Epidemiology European Journal of Neurology General Hospital Psychology Health and Quality of Life Outcomes Human Brain Mapping Journal of Neurology, Neurosurgery and Psychiatry Journal of the Neurological Sciences Mayo Clinic Proceedings Mult iple Sclerosis and Related Diseases Multiple Sclerosis Journal Nature Reviews Neurology NeuroImage 3 NeuroImage: Clinical Practice Neurology Neurology Clinical Practice Neurology: Neuroimmunology and Neuroinflammation Pharmacogenomics PLOS Computational Bio logy Quality of Life Research Statistical Applications in Genetics and Molecular Biology Statistics in Medicine Other Editorial Roles 2008- Editorial review board Statistical Methods in Medical Research Honors and Prizes 1999 Sigma Xi Brown University National scientific research honor society 1999 Tau Beta Pi Brown University National engineering honor society 2000 American Institute of Chemists Foundation Student Achievement Award Brown University Awarded to top chemical engineering student 2002 Howard Hughes Medical Institute Predoctoral Fellowship in Biological Sciences Honorable Mention Howard Hughes Medical Institute 2002 Excellence in Teaching Harvard University, Department of Biostatistics 2004 Excellence in Teaching Harvard University, Department of Biostatistics 2016 Pickard Award for Teaching and Mentoring Harvard University, Department of Statistics Awarded to junior faculty member at Harvard University Report of Funded and Unfunded Projec ts Funding Information Past 2002-2006 NIH NIAID (HIV Training Grant) T32 AI007358-17 Role: Graduate Student Modeled acquisition of HIV drug resistance mutations 2009-2012 ECOR 4 Massachusetts General Hospital Role: Biostatistics educator Design and conduct introductory biostatistics course 2009-2014 EMD Serono Comprehensive longitudinal investigation of multiple sclerosis at the Brigham and Women’s Hospital Role: Biostatistician Biostatistics support for study 2010-2013 NMSS Biomarkers and risk factors for disease progression in multiple sclerosis Role: Biostatistician Performed data analysis and interpretation 2012-2014 NIH/NINDS Novel approaches for the modeling of disease progression in multiple sclerosis Role: Biostatistician Developed statistical models for disease progression 2011-2014 NMSS Magnetic resonance disease severity scale for multiple sclerosis Role: Biostatistician 2013-2014 CMSC Long-term patient reported outcomes in pediatric onset multiple sclerosis Role: Biostatistician Performed data analysis and interpretation 2014-2015 Genzyme Post-partum MRI changes in women with MS Role: Biostatistician Performed data analysis and interpretation 2013-2018 NIH/NHBLI Developing a positive psychology intervention to improve cardiac health behaviors Ro le: Biostatistician Designed and analyzed the data from positive psychology interventions 2013-2018 NIH/NCATS (NCRR) Harvard Clinical and Translational Science Center Role: Biostatistics education Developed and taught in multiple Catalyst post graduate education programs 2009-2018 EMD Serono Inc CLIMB Study Role: Co-investigator/biostatistician Created analysis datasets and performed analyses related to disease progression in MS 2013-2018 NIH Circulating microRNAs as disease biomarkers in multiple sclero sis Role: Biostatistician Identified miRNAs associated with disease category, disability, and treatment response for subjects with MS 2015-2016 NMSS A phase I randomized controlled trial to improve speed of information processing in patients with MS Role: Co -investigator/biostatistician 5 Designed a clinical trial to assess the tolerability and efficacy of a speed of information processing training 2018-2019 CMSC A phase I randomized controlled trial of a positive psychology intervention for patie nts with multiple sclerosis Role: Co-investigator/biostatistician Design a phase I trial for positive psycho logy and analyze results from the study 2018 Brigham Research Institute BRI patient -centered comparative effectiveness research center pilot award Role: Principal Investigator Develop a patient engagement panel and create questionnaires to identify resear ch questions of most interest to MS patients Current 2015-2019 Verily Sciences LLC SysteMS: a systems biology study of clinical, radiological, and molecular markers in subjects with multiple sclerosis Role: Co-investigator/biostatistician Analyze data from multiple sources to identify predictors of disease progression 2017-2022 NIH/NHBLI Pragmatic collaborative care fo r cardiac inpatients with depression or anxiety Role: Co-investigator/biostatistician Analyze and interpret data from clinical trial of collaborative care 2018-2023 NIH/NCATS (NCRR) Harvard clinical and translational science center Role: Biostatistics education Developed and taught in multiple Catalyst post graduate education programs 2018-2021 DOD/CDMRP Study of immune-based biomarkers using the longitudinal CLIMB dataset Role: Co-investigator/biostatistician Identify single and sets of biomarkers predict ive of disease progression 2019-2020 Analysis Group Prognostic Factors for Disease Progression in Multiple Sclerosis Role: Principal Investigator Total direct costs: $230,008 Identify short term measures of disease progression to supplement confirmed disability accumulation Report of Local Teaching and Training Teaching of Students in Courses Past 2002-2004 Principles of Biostatistics Harvard School of Public Health 1st year MPH students 12 two-hour lab sessions 2004-2005 Principles of Biostatistics I Harvard School of Public Health 1st year MPH students 15 two-hour lab sessions 6 2005 Summer institute computing and real analysis courses Harvard School of Public Health 1st year biostatistics graduate students 10 two-hour lectures 2005 Applied Longitudinal Analysis Harvard School of Public Health 2nd year graduate students 3 two-hour lab sessions 2006 Summer institute methods course Harvard School of Public Health 1st year biostatistics graduate students 15 two-hour lectures 2009-2011, 2013 Principles of Biostatistics II 1st year MPH students Harvard School of Public Health 15 two-hour lectures 2014-2017 Introduction to Survival Analysis 2nd year MS students Harvard School of Public Health/ King Abdulaziz University 7 recorded lectures 10 two hour sessions 2015 Master’s Program in Clinical and Translational Investigation Two week intensive summer course with seven longitudinal sessions throughout the fall 2016 Program in Clinical and Translational Science Two week intensive summer course with seven longitudinal sessions throughout t he fall Current 2015- Introduction to Epidemiology and Biostatistics: ID207-208 1st year MPH students Harvard School of Public Health 10 two hour lectures and six weeks of on- line program 2017- Harvard Catalyst CT Academy Two week intensive summer course with seven longitudinal sessions throughout the fall 2017- Brigham and Women’s Hospital Clinical Investigation Track Statistics bootcamp (6 sessions) 2012- Portugal Clinical Scholars Research Training 10 lectures for introductory course 4 lectures for survival analysis unit 4 lectures for correlated outcomes unit Multiple webinars Led in person workshops 2013- Global Clinical Scholars Research Training 10 lectures for introductory course 4 lectures for survival analysis unit 4 lectures for correlated outcomes unit Multiple webinars 2019 Summer symposium on "Big data for Health" for Latin American investigators 1 three-hour lecture related to regression Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs) 2007 Introduction to biostatistics BWH MS researchers 4 one-hour lectures 2008 Introduction to correlated data methods BWH Medical imaging researchers 4 one-hour lectures 2010 Introduction to biostatistics MGH 7 Department of Pediatric Endocrinology 4 one-hour lectures 2010 Introduction to biostatistics MGH Department of Pathology 4 one-hour lectures 2015 An introduction to samp le size calculations Department of Endocrinology 1 one-hour lecture 2019- Models of Disease Boot Camp Post graduate medical researchers 2 one-hour lectures related to introductory statistics Fo rmal Teaching of Peers (e.g., CME and other continuing education courses) No presentations below were sponsored by outside entities 2010- Introduction to Biostatistics for Clinical Scient ists Massachusetts General Hospital Clinical researchers 5 one and a half-hour lectures 2013-2018 “Statistical reasoning: part 1” and “Statistical reasoning: part 2” Introduction to Clinical Investigation Harvard Catalyst 2 one hour lectures 2013 “Fro m Biologic Insights to Trial Design” with Dr. Elliott Antman Introduction to Clinical Investigation Harvard Catalyst 1 one and a half hour lecture 2013-2018 “Workshop: T2” with Dr. Elliott Antman Introduction to Clinical Investigation Harvard Catalyst 1 one and a half hour lecture 2014- “Biostatistics in T2/T3 research” FaCToR – Fundamentals of Clinical and Translational Research 5 recorded lecture segments 2015- “Case study: How to evaluate a biomarker” Understanding Biomarker Science Harvard Catalyst 1 one hour lecture 2016- “Case study: How to evaluat e a biomarker: Part 2” Understanding Biomarker Science Harvard Catalyst 1 one hour lecture 2016- “Regression adjustment and logistic regression” Comparative Effectiveness Research Harvard Catalyst 5 recorded lecture segments 2017- “Multiple comparisons and power/sample size” Introduction to Omics Research Harvard Catalyst 2 recorded lecture segments Laboratory and Other Research Supervisory and Training Responsibilities 2009-2012 Open office hour for statistical consultation at MGH Biostatistics Center Two hours per week Local Invited Presentations No presentations below were sponsored by outside entities 2006 HIV working group Department of Biostatistics, HSPH 8 2008 Neurostatistics working group Department of Biostatistics, HSPH 2014 “Modeling disease progression in MS patients” Neurostatistics working group Department of Biostatistics, HSPH 2014 “Use of observational data to make causal inferences about treatment decisions in multiple sclerosis” Statistical Issues in the Analysis of Neurological Studies A Harvard Catalyst Biostatistics Symposium 2014 “Measurement issues in short term clinical trials of multiple sclerosis” Statistical Issues in the Analysis of Neurological Studies A Harvard Catalyst Biostatistics Symposium Report of Regional, National and International Invited Teaching and Presentations Invited Presentations and Courses No presentations below were sponsored by outside entities National 2008 “Combining Retrospective and Prospective Data in Characterizing Accumulation of Antiviral Resistance Mutations” give n to Statistics Department seminar series Brigham Young University 2010 “Optimal design and analysis of phase I/II clinical trials in multiple sclerosis with gadolinium enhancing lesions as the endpo int” (abstract) 62nd annual American Academy of Neurology 2014 “Teaching statistics to medical researchers using an on-line program: experience from the Harvard Catalyst Certificate in Applied Biostatistics”; Joint Statistical Meetings 2014 2015 “Developing on-line resources to teach biostatistics to working medical researchers”; Joint Statistical Meeting 2015 2016 “Using a journal club to review and reinforce concepts for medical researchers ”; Jo int Statistical Meeting 2016 2019 “Analysis of disease progression in patients with multiple sclerosis”; given to the Department of Biostatistics seminar series at the University of Alabama Birmingham 2019 “Impact of approaches for clinical and radiological monitoring on predicting of short-term and long-term disability outcomes in multiple sclerosis”; Joint Statistical Meeting 2019 International 2019 “The study of treatment effect modifiers: examples in MS ” given to European Committee for Treatment and Research in Multiple Sclerosis Summer School 2019 in Methodology of clinical research and statistics 2019 “Clinical trials: from animal models to phase 3. The standard designs in MS” given to European Committee for Treatment and Research in Multiple Sclerosis Summer School 2019 in Methodology of clinical research and statistics Report of Education of Patients and Service to the Community 9 Educational Material for Patients and the Lay Communi ty Patient educational material 2008-2010 Partners MS Center newsletter Contributor Patient education pamphlet 2018 Partners Patient Engagement Panel Co-director Semi-annual meetings of MS researchers and MS patients to discuss research directions Report of Scholarship Publications Peer reviewed publications in print or other media 1. Abdel-Wahab OI, Healy B, Dzik WH. Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulat ion abnormalities. Transfusion 2006;46:1279- 1285 2. Healy B, DeGruttola V. Hidden Markov models for settings with interval-censored transition times and uncertain time origin: application to HIV genetic analyses. Biostatistics 2007;8(2):438- 52 3. Rodriguez JR, Madanat MG, Healy BC, Thayer SP, Warshaw AL, Castillo CF. Distal pancreatectomy with splenic preservation revisited. Surgery 2007;141(5):619-25 4. Healy B, De Gruttola V, Pagano M. Combining Cross-Sectional and Prospective Data Methods to Improve Transition Parameter Estimation for Characterizing the Accumulation of HIV-1 Drug Resistance Mutations. Biometrics 2007;63(3):742-750 5. Healy BC, DeGruttola VG, and Hu C. Accommodating Uncertainty in a Tree Set for Function Estimation. Statistical Applications in Genetics and Molecular Biology 2008;7(1):5. 6. Viglietta V, Bourcier K, Buckle GJ, Healy BC, Weiner HL, Hafler DA, Egorova S, Guttmann CRG, Rusche JR, Khoury SJ. CTLA4Ig treatment in patients with multiple sclerosis: an open- label, phase I clinical trial. Neurology 2008;71(12):917-24. 7. Liptak Z* and Berger AM*, Sampat MP, Charil A, Fe lsovalyi O, Healy BC, Khoury SJ, Weiner HL, Bakshi R, Guttma nn CRG. Medulla Oblongata Volume: A Biomarker of Spinal Cord Damage and Disability in Multiple Sclerosis. American Journal of Neuroradiology 2008;29:1465-1470 8. Bakshi R, Neema M, Healy BC, Liptak Z, Betensky RA, Buckle GJ, Gauthier SA, Stankiewicz J, Meier D, Egorova S, Arora A, Guss ZD, Glanz B, Khoury SJ, Guttmann CRG, Weiner HL. Magnetic Resonance Disease Severity Scale (MRDSS) predicts clinical progression in multip le sclerosis. Archives of Neurology 2008;65 (11):1449-1453. 9. Healy BC, Hayden DL, Sampat M, Bakshi R, Guttmann CRG. Unbiased treatment effect 10 est imates by modeling the disease process of multiple sclerosis. Journal of the Neurological Sciences 2009;278: 54-9. 10. Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediat ric-onset compared to adult-onset multiple sclerosis. Archives of Neurology 2009;66(1):54-9. 11. Neema M, Arora A, Healy BC, Guss ZD, Brass SD, Duan Y, Buckle GJ, Glanz B, Stazzone L, Khoury SJ, Weiner HL, Guttmann CRG, Bakshi R. Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. Journal of Neuroimaging 2009;19:3-8. 12. Stankiewicz JM, Neema M, Alsop DC, Healy BC, Arora A, Buckle GJ, Chitnis T, Guttmann CRG, Hackney D, Bakshi R. Spinal cord lesions and c linical status in multiple sclerosis: A 1.5 T and 3 T MRI study. Journal of the Neurological Sciences 2009;279:99-105. 13. Ali EN, Healy BC, Stazzone LA, Brown BA, Weiner HL, Khoury SJ. Daclizumab in treatment of multiple sclerosis patients. Multiple Sclerosis 2009;15(2):272-4. 14. Healy BC, Valsasina P, Filippi M, Bakshi R. Sample size requirements for treatment effects using gray matter, white matter and whole brain volume in relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry. 2009 Nov;80(11):1218-23. doi: 10.1136/jnnp.2008.154732. 15. Healy BC and Engler D. Modeling disease-state transition heterogeneity through Bayesian variable selectio n. Statistics in Medicine 2009;28(9):1353-68. 16. Neema M, Goldberg-Zimring D, Guss ZD, Healy BC, Guttmann CR, Hout chens MK, Weiner HL, Horsfield MA, Hackney DB, Alsop DC, Bakshi R (2009) 3T MRI relaxometry detects T2 prolongation in the cerebral normal-appearing white matter in multiple sclerosis, Neuroimage 2009 Jul 1;46(3):633-41. 17. Chitnis T, Glanz B, Jaffin S, Healy BC. Demographics of pediatric-onset multiple sclerosis in an MS Center population from the Northeastern United States. Multiple Sclerosis 2009 May;15(5):627-31. 18. Maier LM, Anderson DE, Severson CA, Baecher-Allan C, Healy B, Liu DV, Wittrup KD, De Jager PL, Hafler DA. Soluble IL-2RA Levels in Mult iple Sclerosis Subjects and the Effect of Soluble IL-2RA on Immune Responses. Journal of Immunology 2009;182(3):1541-7. 19. Ceccarelli C, Filippi M, Neema M, Arora A, Valsasina P, Rocca MA, Healy BC, Bakshi R T2 hypointensity in the deep gray matter of patients with benign multiple sclerosis, Multiple Sclerosis 2009;15(6):678-86. 20. Neema M, Guss ZD, Stankiewicz J, Arora A, Healy BC, Bakshi R Normal findings on brain FLAIR MRI scans at 3T, AJNR American Journal of Neuroradiology 2009;30(5):911-6. 21. Mo scufo N, Guttmann CR, Meier D, Csapo I, Hildenbrand PG, Healy BC, Schmidt JA, Wolfson L (2009) Brain regional lesion burden and impaired mobility in the elderly. Neurobiol Aging. 11 2009 May 8. [Epub ahead of print] 22. Kivisäkk P, Healy BC, Viglietta V, Quintana FJ, Hootstein MA, Weiner HL, Khoury SJ. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology. 2009;72(22):1922-30. 23. Sampat MP, Sander C, Berger A, Healy B, Felsovalyi OL, Hildenbrand P, Meier D, Bakshi R, Guttmann CRG Regional white matter atrophy based classification of MS in cross-sectional and longitudinal data, AJNR American Journal of Neuroradiology, 2009 Oct;30(9):1731-9. Epub 2009 Aug 20. 24. Healy BC, Ali E, Guttmann CRG, Chitnis T, Glanz BI, Buckle G, Houtchens M, Stazzone L, Moodie J, Berger AM, Duan Y, Bakshi R, Khoury S, Weiner H, Ascherio A. Smoking and disease progression in multiple sclerosis. Archives of Neurology. 2009 Jul;66(7):858-64. 25. Vishwas M, Chitnis T, Pie naar R, Healy BC, Grant PE. Tract Based Analysis of callosal Project and Associatio n Pathways in Pediatric Patients with Multiple Sclerosis. AJNR American Journal of Neuroradiology, 2009 Oct 22 [Epub ahead of print] 26. Stankiewicz JM, Glanz BI, Healy BC, Arora A, Neema M, Benedict RH, Guss ZD, Tauhid S, Buckle GJ, Ho utchens MK, Khoury SJ, Weiner HL, Guttmann CR, Bakshi R. Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis. J Neuroimaging. 2009 Nov 3 [Epub ahead of print] 27. Glanz BI, Healy BC, Rintell DJ, Jaffin SK, Bakshi R, Weiner HL. The association between cognitive impairment and quality o f life in patients with early multiple sclerosis. J Neurol Sci. 2010 Mar 15;290(1-2):75-9. 28. Sampat MP, Healy BC, Meier DS, Dell'oglio E, Liguori M, Guttmann CR. Disease modeling in multiple sclerosis: Assessment and quantification of sources of variability in brain parenchymal fraction measurements. Neuroimage. 2010 Apr 1. [Epub ahead of print] PMID: 20362675 29. Healy BC, Ikle D, Macklin EA, Cutter G. Optimal design and analysis of phase I/II clinical trials in multiple sclerosis with gadolinium-enhanced lesions as the endpoint. Mult Scler. 2010 Jul;16(7):840-7. 30. Healy BC, Liguori M, Tran D, Chitnis T, Glanz B, Wolfish C, Gauthier S, Buckle G, Houtchens M, Stazzone L, Khoury S, Hartzmann R, Fernandez-Vina M, Hafler DA, Weiner HL, Guttmann CR, De Jager PL. HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology. 2010 Aug 17;75(7):634-40.PMID: 20713950 31. Healy BC, Glanz BI, St ankiewicz J, Buckle G, Weiner H, Chitnis T. A method for evaluating treatment switching criteria in multiple sclerosis. Mult Scler. 2010 Dec;16(12):1483-9. PMID: 20736245 32. Meier DS, Balashov KE, Healy B, Weiner HL, Guttmann CR. Seasonal prevalence of MS disease activity. Neurology. 2010 Aug 31;75(9):799-806.PMID: 20805526 12 33. Xiao D, Cassin JJ, Healy B, Burdett TC, Chen JF, Fredholm BB, Schwarzschild MA. Deletion of adenosine A(1) or A(2A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease. Brain Res. 2010 Sep 6. [Epub ahead of print]PMID: 20828543 34. Khoury SJ, Healy BC, Kivisäkk P, Vigliet ta V, Egorova S, Guttmann CR, Wedgwood JF, Hafler DA, Weiner HL, Buckle G, Cook S, Reddy S. A Randomized Controlled Double-Masked Trial of Albuterol Add-on Therapy in Patients With Multiple Sclerosis. Arch Neurol. 2010 Sep;67(9):1055-61.PMID: 20837847 35. Gross R, Healy BC, Cepok S, Chitnis T, Khoury SJ, Hemmer B, Weiner HL, Hafler DA, De Jager PL. Population structure and HLA DRB1*1501 in the response of subjects with multiple sclerosis to first -line treatments. J Neuroimmunol. 2011 Apr;233(1-2):168-74. PMID: 21115201 36. Liguori M, Healy BC, Glanz BI, Khoury SJ, Moscufo N, Weiner HL, De Jager PL, Guttmann CR. HLA (A-B-C and -DRB1) alleles and brain MRI changes in multiple sclerosis: a longitudinal study. Genes Immun. 2011 Apr;12(3):183-90. PMID: 21179117 37. Healy BC, Engler D, Gholipour T, Weiner H, Bakshi R, Chitnis T. Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis. J Neurol Sci. 2011 Apr 15;303(1-2):109-13. PMID: 21251671 38. Mike A, Glanz BI, Hildenbrand P, Meier D, Bolden K, Liguori M, Dell'oglio E, Healy BC, Bakshi R, Guttmann CR. Identification and Clinical Impact of Multiple Sclerosis Cortical Lesions as Assessed by Routine 3T MR Imaging. AJNR Am J Neuroradiol. 2011 Mar;32(3):515-21. PMID: 21310857 39. Hviid LE, Healy BC, Rintell DJ, Chitnis T, Weiner HL, Glanz BI. Patient reported outcomes in benign multiple sclerosis. Mult Scler. 2011 Jul;17(7):876-84. PMID: 21372114 40. Huffman JC, Mastromauro CA, Sowden G, Fricchione GL, Healy BC, Januzzi JL. Impact of a depression care management program for hospitalized cardiac patients. Circ Cardiovasc Qual Outcomes. 2011 Mar 1;4(2):198-205. PMID: 21386067 41. Liguori M, Meier DS, Hildenbrand P, Healy BC, Chitnis T, Baruch NF, Khoury SJ, Weiner HL, Bakshi R, Barkhof F, Guttmann CR. One year activity on subtraction MRI predicts subsequent 4 year activity and pro gression in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2011 Oct;82(10):1125-31. PMID: 21429902 42. Healy B, Chitnis T, Engler D. Improving power to detect disease progression in multiple sclerosis through alternative analysis strategies. J Neurol. 2011 Oct;258(10):1812-9. PMID: 21472497 43. Gho lipour T, Healy B, Baruch NF, Weiner HL, Chitnis T. Demographic and clinical characteristics of malig nant multiple sclerosis. Neurology. 2011 Jun 7;76(23):1996-2001. PMID: 21646626 44. Klein JP, Arora A, Neema M, Healy BC, Tauhid S, Goldberg-Zimring D, Chavarro-Nieto C, Stankiewicz JM, Cohen AB, Buckle GJ, Houtchens MK, Ceccarelli A, Dell'oglio E, Guttmann CR, Alsop DC, Hackney DB, Bakshi R. A 3T MR Imaging Investigation of the Topography of 13 Whole Spinal Cord Atrophy in Multiple Sclerosis. AJNR Am J Neuroradiol. 2011 Jun;32(6):1138-42. PMID: 21527570 45. Glanz BI, Healy BC, Hviid LE, Chitnis T, Weiner HL. Cognitive deterioration in patient s with early multiple sclerosis: a 5-year study. J Neurol Neurosurg Psychiatry. 2012 Jan;83(1):38-43. PMID: 21746743 46. Healy BC, Arora A, Hayden DL, Ceccarelli A, Tauhid SS, Neema M, Bakshi R. Approaches to Normalization of Spinal Cord Volume: Application to Multiple Sclerosis. J Neuroimaging. 2012 Jul;22(3):e12-9. PMID: 21854479 47. Harris JP, Capadona JR, Miller RH, Healy BC, Shanmuganathan K, Rowan SJ, Weder C, Tyler DJ. Mechanically adaptive intracortical implants improve the proximity of neuronal cell bod ies. J Neural Eng. 2011 Dec;8(6):066011. Epub 2011 Nov 2. 48. Moodie J, Healy BC, Buckle GJ, Gauthier SA, Glanz BI, Aro ra A, Ceccarelli A, Tauhid S, Han XM, Venkataraman A, Chitnis T, Khoury SJ, Guttmann CR, Weiner HL, Neema M, Ba kshi R. Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: A longitudinal study. J Neurol Sci. 2012 Apr 15;315(1-2):49-54. PMID: 22209496 49. Healy BC, Degano IR, Schreck A, Rintell D, Weiner H, Chitnis T, Glanz BI. The impact of a recent relapse on patient-reported outcomes in subjects with multiple sclerosis. Qual Life Res. 2012 Dec;21(10):1677-84. PMID: 22237991 50. Vishwas MS, Healy BC, Pienaar R, Gorman MP, Grant PE, Chitnis T. Diffusion Tensor Analysis of Pediatric Multiple Sclerosis and Clinically Isolated Syndromes. AJNR Am J Neuroradiol. 2013 Feb;34(2):417-23. 51. Healy BC, Schoenfeld D. Comparison of analysis approaches for phase III clinical trials in amyotrophic lateral sclerosis. Muscle Nerve. 2012 Oct;46(4):506-11. doi: 10.1002/mus.23392. a. Healy BC, Schoenfeld D. Reply. Muscle Nerve. 2013 May;47(5):779-80. doi: 10.1002/mus.23727. Epub 2013 Mar 27. 52. Glanz BI, Dégano IR, Rintell DJ, Chitnis T, Weiner HL, Healy BC. Work productivity in relapsing multiple sclerosis: associations with disability, depression, fatigue, anxiety, cognition, and health-related quality of life. Value Health. 2012 Dec;15(8):1029-35. doi: 10.1016/j.jval.2012.07.010. Epub 2012 Oct 25. 53. Gandhi R, Healy B, Gholipour T, Egorova S, Musallam A, Shuja M, Nejad P, Patel B, Hei H, Khoury S, Quintana F, Kivisakk P, Chitnis T, Weiner HL.Circulating microRNAs as biomarkers for disease staging in multiple sclerosis.Ann Neurol. 2013 Jun;73(6):729-40. 54. Benedict RH, Schwartz CE, Duberstein P, Healy B, Hoogs M, Bergsland N, Dwyer MG, Weinst ock-Guttman B, Zivadinov R. Influence of personality on the relationship between gray matter volume and neuropsychiatric symptoms in multiple sclerosis. Psychosom Med. 2013 Apr;75(3):253-61. doi: 10.1097/PSY.0b013e31828837cc. 14 55. Bove R, Secor E, Healy BC, Musallam A, Vaughan T, Glanz BI, Greeke E, Weiner HL, Chitnis T, Wicks P, De Jager PL. Evaluation of an online platform for multiple sclerosis research: patient description, validation of severity scale, and exploration of BMI effects on disease course. PLoS One. 2013;8(3):e59707. doi: 10.1371/journal.pone.0059707. 56. Healy BC, Engler D, Glanz B, Musallam A, Chitnis T. Assessment of definitions of sustained disease progression in relapsing-remitting multiple sclerosis. Mult Scler Int. 2013;2013:189624. doi: 10.1155/2013/189624. Epub 2013 Mar 10. 57. Bove RM, Brick DJ, Healy BC, Mancuso SM, Gerweck AV, Bredella MA, Sherman JC, Miller KK. Metabolic and endocrine correlates of cognitive function in healthy young women. Obesity (Silver Spring). 2013 Jul;21(7):1343-9. 58. Schwartz CE, Quaranto BR, Healy BC, Benedict RHB, Vollmer TL. Altruism and health outcomes in multiple sclerosis: the effect of cognitive reserve. Journal of Positive Psychology 2013; 8(2)144-152. 59. Schwartz CE, Quaranto BR, Healy BC, Benedict RH, Vollmer TL. Cognitive reserve and symptom experience in multiple sclerosis: A buffer to disability progression over time? Arch Phys Med Rehabil. 2013 Oct;94(10):1971-81. 60. Li J, Healy BC, Chitnis T, Brodley CE. Removing Confounding Factors via Constraint-Based Clustering: An Application to Finding Homogeneous Groups of MS Patients. IEEE Proceedings of ICHI 2013. 61. Beach SR, Januzzi JL, Mastromauro CA, Healy BC, Beale EE, Celano CM, Huffman JC. Patient Health Questionnaire-9 score and adverse cardiac outcomes in patients hospitalized for acute cardiac disease. J Psychosom Res. 2013 Nov;75(5):409-13. 62. Schwartz CE, Quaranto BR, Rapkin BD, Healy BC, Vollmer T, Sprangers MA. Fluctuations in appraisal over time in the context of stable versus non-stable health. Qual Life Res. 2014 Feb;23(1):9-19. PMID: 23851975 63. Bove R, Musallam A, Healy BC, Houtchens M, Glanz BI, Khoury S, Guttmann CR, De Jager PL, Chitnis T. No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50. BMC Neurol. 2013 Jul 3;13:73. doi: 10.1186/1471-2377-13-73. 64. Kivisäkk P, Healy BC, Francois K, Gandhi R, Gholipour T, Egorova S, Sevdalinova V, Quintana F, Chitnis T, Weiner HL, Khoury SJ. Evaluation of circulating osteopontin le vels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. Mult Scler. 2014 Apr;20(4):438-44. PMID: 24005026 65. Ottoboni L, Frohlich IY, Lee M, Healy BC, Keenan BT, Xia Z, Chitnis T, Guttmann CR, Khoury SJ, Weiner HL, Hafler DA, De Jager PL. Clinical relevance and functional consequences of the TNFRSF1 A multiple sclerosis lo cus. Neurology. 2013 Nov 26;81(22):1891-9. doi: 10.1212/01.wnl.0000436612.66328.8a. PMID: 24174586 66. Messina S, Vargas-Lowy D, Musallam A, Healy B, Healy BC, Gandhi R, Bove R, Gholipour T, 15 Khoury S, Weiner HL, Chitnis T. Increased leptin and A-FABP levels in relapsing and progressive forms of MS. BMC Neurol. 2013 Nov 11;13(1):172. PMID: 24215402 67. Carruthers RL, Chitnis T, Healy BC. Modeling probability of additional cases of natalizumab- associated JCV sero -negative progressive multifoc al leukoencephalopathy. Mult Scler. 2014 May;20(6):757-60. PMID: 24189572 68. Minden SL, Ding L, Cleary PD, Frankel D, Glanz BI, Healy BC, Rintell DJ. Improving the quality of mental health care in multiple sclerosis.J Neurol Sci. 2013 Dec 15;335(1-2):42-7. PMID: 24183855 69. Chitnis T, Guttmann CR, Zaitsev A, Musallam A, Weinstock-Guttmann B, Yeh A, Rodriguez M, Ness J, Gorman M, Healy BC, Kuntz N, Chabas D, Strober JB, Waubant E, Krupp L, Pelletier D, Erickson B, Bergsland N, Zivadinov R. Quantitative MRI analysis in children with multiple sclerosis: a multicenter feasibility pilot study.BMC Neurol. 2013 Nov 13;13(1):173. PMID: 24225378 70. Huffman JC, Dubois CM, Healy BC, Boehm JK, Kashdan TB, Celano CM, Denninger JW, Lyubomirsky S. Feasibility and utility of positive psychology exercises for suicidal inpatients. Gen Hosp Psychiatry. 2014 Jan-Feb;36(1):88-94. PMID: 24230461 71. Bove R, Musallam A, Healy B, Raghavan K, Glanz B, Bakshi R, Weiner H, De Jager P, Miller K, Chitnis T. Low testosterone is associated with d isability in men with multiple sclerosis. Mult Scler. 2014 Apr 7. [Epub ahead of print] 72. Huffman JC, Mastromauro CA, Beach SR, Celano CM, Dubois CM, Healy BC, Suarez L, Rollman BL, Januzzi JL. Collaborative Care for Depression and Anxiety Disorders in Patients With Recent Cardiac Events: The Management of Sadne ss and Anxiety in Cardiology (MOSAIC) Randomized Clinical Trial. JAMA Intern Med. 2014 Jun;174(6):927-35. 73. Carruthers RL, Rotstein DL, Healy BC, Chitnis T, Weiner HL, Buckle GJ. An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy. Mult Scler. 2014 Sep; 20(10):1381-90. 74. Malik MT, Healy BC, Benson LA, Kivisakk P, Musallam A, Weiner HL, Chitnis T. Factors associated with recovery from acute optic neuritis in p atients with multiple sclerosis. Neurology. 2014 Jun 17;82(24):2173-9. 75. Glanz BI, Musallam A, Rintell DJ, Chitnis T, Weiner HL, Healy BC. Treatment satisfaction in multiple sclerosis. Int J MS Care. 2014 Summer; 16(2):68-75. 76. Raghavan K, Healy BC, Carruthers RL, Chitnis T. Progression rates and sample size est imates for PPMS based on the CLIMB study population. Mult Scler. 2014 Jul 28. pii: 1352458514541976. [Epub ahead of print] 77. Tauhid S, Neema M, Healy BC, Weiner HL, Bakshi R. MRI phenotypes based on cerebral lesions and atro phy in patients with multiple sclerosis. J Neurol Sci. 2014 Sep 6. pii: S0022- 510X(14)00579-6. doi: 10.1016/j.jns.2014.08.047. [Epub ahead of pr int] 16 78. Bakshi R, Neema M, Tauhid S, Healy BC, Glanz BI, Kim G, Miller J, Berkowitz JL, Bove R, Houtchens MK, Severson C, Stankiewicz JM, Stazzone L, Chitnis T, Guttmann CR, Weiner HL, Ceccarelli A. An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2. Neuroreport. 2014 Oct 1;25(14):1156-61. 79. Curran JM, Healy BC. The loyalty continuum: differentiating between stages of loyalty development. Journal of Marketing Theory and Practice. 2014; 22(4): 367-384. 80. Dell'Oglio E, Ceccarelli A, Glanz BI, Healy BC, Tauhid S, Arora A, Saravanan N, Bruha MJ, Vartanian AV, Dupu y SL, Benedict RH, Bakshi R, Neema M. Quantification of global cerebral atrophy in multiple sclerosis from 3T MRI using SPM: the role of misclassification errors . Journal of Neuroimaging 2014 Dec 18. [Epub ahead of print] PubMed PMID: 25523616 81. Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort.. JAMA Neurol. 2015 Feb;72(2):152-8. doi: 10.1001/jamaneurol.2014.3537. 82. Bove R, Healy BC, Secor E, Vaughan T, Katic B, Chitnis T, Wicks P, De Jager PL. Patients report wo rse MS symptoms after menopause: findings from an online cohort. Mult Scler Relat Disord. 2015 Jan;4(1):18-24. doi: 10.1016/j.msard.2014.11.009. Epub 2014 Dec 9. PMID: 25787049 83. Benson LA, Healy BC, Gorman MP, Baruch NF, Gholipour T, Musallam A, Chitnis T. Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years. Mult Scler Relat Disord. 2014 Mar;3(2):186-93. doi: 10.1016/j.msard.2013.06.004. Epub 2013 Jul 12. 84. Fernandez-Carbonell C, Vargas-Lowy D, Musallam A, Healy B, McLaughlin K, Wucherpfennig KW, Chitnis T. Clinical and MRI phenotype of children with MOG antibodies. Mult Scler. 2015 Jun 3. pii: 1352458515587751. [Epub ahead of print] PMID: 26041801 85. Baruch NF, O'Donnell EH, Glanz BI, Benedict RH, Musallam AJ, Healy BC, Rintell D, Chit nis T. Cognitive and patient -reported outcomes in adults with pediatric-onset multiple sclerosis. Mult Scler. 2015 Jun 3. pii: 1352458515588781. [Epub ahead of print] PMID: 26041802 86. Engler DA, Chitnis T, Healy B. Joint assessment of dependent discrete disease state processes. Statistical Methods in Medical Research. 2015. doi: 10.1177/0962280215569899. 87. DuBois CM, Lopez OV, Beale EE, Healy BC, Boehm JK, Huffman JC. Relationships between positive psychological constructs and health outcomes in patients with cardiovascular disease: A systematic review. Int J Cardiol. 2015 Sep 15;195:265 -280. doi: 10.1016/j.ijcard.2015.05.121. Epub 2015 May 21. Review. PMID: 26048390 88. Chua AS, Egorova S, Anderson MC, Polgar-Turcsanyi M, Chitnis T, Weiner HL, Guttmann CR, Bakshi R, Healy BC. Using multiple imputation to efficiently correct cerebral MRI whole brain lesion and atrophy data in patients with multiple sclerosis. Neuroimage. 2015 Jun 17. pii: S1053- 8119(15)00540-6. doi: 10.1016/j.neuroimage.2015.06.037. [Epub ahead of print] PMID: 26093330 17 89. Chu R, Tauhid S, Glanz BI, Healy BC, Kim G, Oommen VV, Khalid F, Neema M, Bakshi R. Whole Brain Volume Measured from 1.5T versus 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis. J Neuroimaging. 2015 Jun 28. doi: 10.1111/jon.12271. [Epub ahead of print] PMID:26118637 90. Carruthers RL, Healy BC. PML in DMF-treated patients with normal lymphocytes: Worried well or well to be worried? Mult Scler. 2015 Jul 10. pii: 1352458515593822. [Epub ahead of print] No abstract available. PMID: 26163066 91. Chua AS, Egorova S, Anderson MC, Polgar -Turcsanyi M, Chitnis T, Weiner HL, Guttmann CR, Bakshi R, Healy BC. Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect models. Neuroimage Clin. 2015 Jul 2;8:606-10. doi: 10.1016/j.nicl.2015.06.009. eCollection 2015. PMID: 26199872 92. Tauhid S, Chu R, Sasane R, Glanz BI, Neema M, Miller JR, Kim G, Signorovitch JE, Healy BC, Chitnis T, Weiner HL, Bakshi R. Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis. J Neurol. 2015 Jul 24. [Epub ahead of print] PMID: 26205635 93. Kim G, Khalid F, Oommen VV, Tauhid S, Chu R, Horsfield MA, Healy BC, Bakshi R. T1- vs. T2-based MRI measures of spinal cord volume in healthy subjects and patients with multiple sclerosis. BMC Neurol. 2015 Jul 31;15:124. doi: 10.1186/s12883-015-0387-0. PMID: 26227960 94. Liu J, Brodle y CE, Healy BC, Chitnis T. Removing confounding factors via constraint -based clustering: An application to finding homogeneous groups of multiple sclerosis patients. Artif Intell Med. 2015 Jul 11. pii: S0933-3657(15)00083-4. doi: 10.1016/j.artmed.2015.06.004. [Epub ahead of print] PMID: 26253753 95. Dobos K, Healy B, Houtchens M. Access to Preventive Health Care in Severely Disabled Women with Multiple Sclerosis. Int J MS Care. 2015 Jul-Aug;17(4):200-5. doi: 10.7224/1537-2073.2013- 046. PMID: 26300706 96. Bove R, Malik MT, Diaz-Cruz C, Chua A, Saraceno TJ, Bargiela D, Greeke E, Glanz BI, Healy BC, Chitnis T. The 2D:4D ratio, a proxy for prenatal androgen levels, differs in men with and without MS. Neurology. 2015 Oct 6;85(14):1209-13. doi: 10.1212/WNL.0000000000001990. Epub 2015 Sep 4. PMID: 26341868 97. Oo mmen VV, Tauhid S, Healy BC, Chua AS, Malik MT, Diaz-Cruz C, Dupuy SL, Weiner HL, Chitnis T, Bakshi R. The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis. J Neuroimaging. 2015 Oct 8. doi: 10.1111/jon.12307. [Epub ahead of print] PMID: 26445919 98. Bove R, Healy BC, Musallam A, Glanz BI, De Jager PL, Chitnis T. Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort. Mult Scler. 2015 Oct 7. pii: 1352458515606211. [Epub ahead of print] PMID: 26447063 18 99. Rotstein DL, Healy BC, Malik MT, Carruthers RL, Musallam AJ, Kivisakk P, Weiner HL, Glanz B, Chitnis T. Effect of vitamin D on MS activity by disease-mo difying therapy class. Neurol Neuroimmunol Neuroinflamm. 2015 Oct 29;2(6):e167. doi: 10.1212/NXI.0000000000000167. eCollection 2015 Dec. 100. Chua AS, Glanz BI, Guarino AJ, Coo k SL, Greeke EE, Little GE, Chitnis T, Healy BC. Patient -reported outcomes in multiple sclerosis: Relationships among existing scales and the development of a brief measure. Mult Scler Relat Disord. 2015 Nov;4(6):598 -606. doi: 10.1016/j.msard.2015.09.004. Epub 2015 Sep 25. 101. Celano CM, Millstein RA, Bedoya CA, Healy BC, Roest AM, Huffman JC. Association between anxiety and mortality in patients with coronary artery disease: A meta-analysis. Am Heart J. 2015 Dec;170(6):1105-15. doi: 10.1016/j.ahj.2015.09.013. Epub 2015 Sep 21. Review. PMID: 26678632 102. Kim G, Tauhid S, Dupuy SL, Tummala S, Khalid F, Healy BC, Bakshi R. An MRI- defined measure of cerebral lesion severity to assess therapeutic effects in multiple sclerosis. J Neurol. 2016 Jan 11. [Epub ahead of print] PMID: 26754005 103. Cavallari M, Palotai M, Glanz BI, Egorova S, Prieto JC, Healy BC, Chitnis T, Guttmann CR. Fatigu e predicts disease worsening in relapsing-remitting multiple sclerosis patients. Mult Scler. 2016 Feb 26. pii: 1352458516635874. [Epub ahead of print] PMID: 26920374 104. Laíns I, Bartosch C, Mondim V, Healy B, Kim IK, Husain D, Miller JW. Second Primary Neoplasms in Patients With Uveal Melanoma: A SEER Database Analysis. Am J Ophthalmol. 2016 May;165:54-64. doi: 10.1016/j.ajo.2016.02.022. Epub 2016 Mar 3. PMID: 26940164 105. Celano CM, Healy B, Suarez L, Levy DE, Mastromauro C, Januzzi JL, Huffman JC. Cost- Effectiveness of a Collaborative Care Depression and Anxiety Treatment Program in Patients with Acute Cardiac Illness. Value Health. 2016 Mar;19(2):185-91. doi: 10.1016/j.jval.2015.12.015. Epub 2016 Feb 6.PMID: 27021752 106. Huffman JC, Boehm JK, Beach SR, Beale EE, DuBois CM, Healy BC. Relationship of optimism and suicidal ideation in three groups of patients at varying leve ls of suicide risk. J Psychiatr Res. 2016 Jun;77:76-84. doi: 10.1016/j.jpsychires.2016.02.020. Epub 2016 Mar 7. PMID: 26994340 107. Khalid F, Tauhid S, Chua AS, Healy BC, Stankiewicz JM, Weiner HL, Bakshi R. A longitudinal uncontrolled study of cerebral gray m atter volume in patients receiving natalizumab for multiple sclerosis. Int J Neurosci. 20 16 May 27. PMID: 27143245 108. Yousuf F, Kim G, Tauhid S, Glanz BI, Chu R, Tummala S, Healy BC, Bakshi R. The Contribution of Cortical Lesions to a Composite MRI Scale of Disease Severity in Multiple Sclerosis. Front Neurol. 2016 Jun 29;7:99. 109. Bove R, Musallam A, Xia Z, Baruch N, Messina S, Healy BC, Chitnis T. Longitudinal BMI trajectories in multiple sclerosis: Sex differences in association with disease severity. Mult Scler Relat Disord. 2016 Jul;8:136-40. doi: 10.1016/j.msard.2016.05.019. Epub 2016 May 31. 19 PMID: 27456889 110. Healy BC, Weinshenker BG. Does early (treatment in) BENEFIT lead to late MS benefit? Neurology. 2016 Aug 10. pii: 10.1212/WNL.0000000000003070. PMID: 27511185 111. Schwartz CE, Rapkin BD, Healy BC. Reserve and Reserve-building activities research: key challenges and future directions. BMC Neurosci. 2016 Sep 15;17(1):62. doi: 10.1186/s12868- 016-0297-0. 112. Regev K, Paul A, Healy B, von Glenn F, Diaz-Cruz C, Gholipour T, Mazzola MA, Raheja R, Nejad P, Glanz BI, Kivisakk P, Chitnis T, Weiner HL, Gandh i R. Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2016 Aug 23;3(5):e267. doi: 10.1212/NXI.0000000000000267. 113. Dupuy SL, Khalid F, Healy BC, Bakshi S, Neema M, Tauhid S, Bakshi R. The effect of intramuscular int erferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis. BMC Med Imaging. 2016 Oct 5;16(1):56. PMID: 27716096 114. Celano CM, Beale EE, Beach SR, Belcher AM, Suarez L, Motiwala SR, Gandhi PU, Gaggin H, Januzzi JL Jr, Healy BC, Huffman JC. Associations Between Psycholog ical Constructs and Cardiac Biomarkers After Acute Coronary Syndrome. Psychosom Med. 2016 Sep 30. PMID: 27749683. 115. Huffman JC, Albanese AM, Campbell KA, Celano CM, Millstein RA, Mastromauro CA, Healy BC, Chung WJ, Januzzi JL, Collins LM, Park ER. The Posit ive Emotions after Acute Coronary Events behavioral health intervention: Design, rationale, and preliminary fea sibility of a factorial desig n study. Clin Trials. 2017 Apr;14(2):128-139. PMID: 28079394 116. Bargiela D, Bianchi MT, Westover MB, Chibnik LB, Healy BC, De Jager PL, Xia Z. Selection of first -line therapy in multiple sclerosis using risk-benefit decision analysis. Neurology. 2017 Feb 14;88(7):677-684. doi: 10.1212/WNL.0000000000003612. PMID: 28087821 117. Kim G, Chu R, Yousuf F, Tauhid S, Stazzone L, Hout chens MK, Stankiewicz JM, Severson C, Kimbrough D, Quintana FJ, Chitnis T, Weiner HL, Healy BC, Bakshi R. Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis. Int J Neurosci. 2017 Feb 2:1-10. doi: 10.1080/00207454.2017.1283313. [Epub ahead of print] PMID: 28100092 118. Regev K, Healy BC, Khalid F, Paul A, Chu R, Tauhid S, Tummala S, Diaz-Cruz C, Raheja R, Mazzola MA, von Glehn F, Kivisakk P, Dupuy SL, Kim G, Chitnis T, Weiner HL, Gandhi R, Bakshi R. Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity. JAMA Neurol. 2017 Jan 23. doi: 10.1001/jamaneurol.2016.5197. [Epub ahead of print] PMID: 28114622 119. Healy BC, Buckle GJ, Ali EN, Egorova S, Khalid F, Tauhid S, Glanz BI, Chitnis T, Guttmann CR, Weiner HL, Bakshi R. Characterizing Clinical and MRI Dissociation in Patients with Multiple Sclerosis. J Neuroimaging. 2017 Mar 6. doi: 10.1111/jon.12433. [Epub ahead of print] PMID: 28261936 20 120. Zhao Y, Healy BC, Rotstein D, Guttmann CR, Bakshi R, Weiner HL, Brodley CE, Chitnis T. Exploration of machine learning techniques in predicting multiple sclerosis disease course. PLoS One. 2017 Apr 5;12(4):e0174866. doi: 10.1371/journal.pone.0174866. eCollection 2017. PMID: 28379999 121. Palotai M, Mike A, Cavallari M, Strammer E, Orsi G, Healy BC, Schregel K, Illes Z, Guttmann CR. Changes to the septo -fornical area might play a role in the pathogenesis of anxiety in multiple sclerosis. Mult Scler. 2017 May 1:1352458517711273. doi: 10.1177/1352458517711273. [Epub ahead of print] PMID: 28548605 122. Sattarnezhad N, Farrow S, Kimbrough D, Glanz B, Healy B, Chitnis T. Agreement analysis comparing iPad LCV A and Sloan testing in multiple sclerosis patients. Mult Scler. 2017 Jun 1:1352458517713667. doi: 10.1177/1352458517713667. [Epub ahead of print] PMID: 28585909 123. Tummala S, Singhal T, Oommen VV, Kim G, Khalid F, Healy BC, Bakshi R. Spinal Cord as an Adjunct to Brain Magnetic Resonance Imaging in Defining "No Evidence of Disease Activity" in Multiple Sclerosis. Int J MS Care. 2017 May-Jun;19(3):158-164. doi: 10.7224/1537- 2073.2016-068. PMID: 28603465 124. Glanz BI, Greeke E, LaRussa A, Stuart F, Rintell DJ, Chit nis T, Healy BC. Risk attitudes and risk perceptions in individuals with multiple sclerosis. Mult Scler J Exp Transl Clin. 2016 Sep 2;2:2055217316665406. doi: 10.1177/2055217316665406. eCollection 2016 Jan-Dec. PMID: 28607735 125. Greeke EE, Chua AS, Healy BC, Rintell DJ, Chitnis T, Glanz BI. Depression and fatigue in patients with multiple sclerosis. J Neurol Sci. 2017 Sep 15;380:236 -241. doi: 10.1016/j.jns.2017.07.047. Epub 2017 Jul 31. PMID: 28870578 126. Diaz-Cruz C, Chua AS, Malik MT, Kaplan T, Glanz BI, Egoro va S, Guttmann CRG, Bakshi R, Weiner HL, Healy BC, Chitnis T. The effect of alcohol and red wine consumption on clinical and MRI outcomes in multiple sclerosis. Mult S cler Relat Disord. 2017 Oct;17:47-53. doi: 10.1016/j.msard.2017.06.011. Epub 2017 Jun 27. PMID: 29055473 127. Eagle T, Stuart F, Chua AS, LaRussa A, Leclaire K, Cook SL, Chitnis T, Weiner HL, Glanz BI, Healy BC. Treatment satisfaction across injectable, infusion, and oral disease- modifying therapies for multiple sclerosis. Mult Scler Relat Disord. 2017 Nov;18:196-201. doi: 10.1016/j.msard.2017.10.002. Epub 2017 Oct 5. PMID: 29141809 128. Yousuf F, Dupuy SL, Tauhid S, Chu R, Kim G, Tummala S, Khalid F, Weiner HL, Ch itnis T, Healy BC, Bakshi R. A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis. J Neurol Sci. 2017 Dec 15;383:221-229. doi: 10.1016/j.jns.2017.10.019. Epub 2017 Oct 16. PMID: 29146095 129. Cavallari M, Egorova S, Healy BC, Palotai M, Prieto JC, Polgar-Turcsanyi M, Tauhid S, Anderson M, Glanz B, Chitnis T, Guttmann CRG. Evaluating the Association between Enlarged Perivascular Spaces and Disease Worsening in Multiple Sclerosis. J Neuroimaging. 20 17 Dec 11. 21 doi: 10.1111/jon.12490. [Epub ahead of print] PMID: 29226505 130. Baharnoori M, Go nzalez CT, Chua A, Diaz-Cruz C, Healy BC, Stankiewicz J, Weiner HL, Chitnis T. Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarat e and impact of treatment switch on lymphocyte and leukocyte count. Mult Scler Relat Disord. 2018 Feb;20:51-57. doi: 10.1016/j.msard.2017.12.003. Epub 2017 Dec 14. PMID: 29304497 131. Tankou SK, Regev K, Healy BC, Cox LM, Tjon E, Kivisakk P, Vanande IP, Cook S, Gandhi R, Glanz B, Stankiewicz J, Weiner HL. Investigation of probiotics in multiple sclerosis. Mult Scler. 2018 Jan;24(1):58-63. doi: 10.1177/1352458517737390. PMID: 29307299 132. Bove R, Healy BC, Musallam A, Soltany P, Diaz-Cruz C, Sattarnezhad N, Glanz BI, Kivisäkk P, Miller KK, Chitnis T. Fatty acid binding prot ein-4 is associated with disability in multiple sclerosis patients. Mult Scler. 2018 Jan 1:1352458517750768. doi: 10.1177/1352458517750768. [Epub ahead of print] PMID: 29320952 133. Raheja R, Regev K, Healy BC, Mazzola MA, Beynon V, Von Glehn F, Paul A, Diaz-Cruz C, Gholipour T, Gla nz BI, Kivisakk P, Chitnis T, Weiner HL, Berry JD, Gandhi R. Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis. Muscle Nerve. 2018 Feb 21. doi: 10.1002/mus.26106. [Epub ahead of print] PMID: 29466830 134. Celano CM, Albanese AM, Millstein RA, Mastromauro CA, Chung WJ, Campbell KA, Legler SR, Park ER, Healy BC, Collins LM, Januzzi JL, Huffman JC. Optimizing a positive psychology intervention to promote health behaviors following an acute coronary syndrome: The Positive Emotions after Acute Coronary Events-III (PEACE-III) randomized factorial trial. Psychosom Med. 2018 Apr 5. doi: 10.1097/PSY.0000000000000584. [Epub ahead of print] PMID: 29624523 135. Leclaire K, Cecil A, LaRussa A, Stuart F, Hemond CC, Healy BC, Chitnis T, Weiner H, Huffman J, Glanz BI. Short Report: A Pilot Study of a Group Positive Psychology Intervention for Patients with Multiple Sclerosis. Int J MS Car e. 2018 May-Jun;20(3):136-141. doi: 10.7224/1537- 2073.2017-002. PMID: 29896050 136. Tankou SK, Regev K, Healy BC, Tjon E, Laghi L, Cox LM, Kivisäkk P, Pierre IV, Hrishikesh L, Gandhi R, Cook S, Glanz B, Stankiewicz J, Weiner HL. A probiotic modulates the microbiome and immunity in multiple sclerosis. Ann Neurol. 2018 Apr 20. doi: 10.1002/ana.25244 137. Hemond CC, Chu R, Tummala S, Tauhid S, Healy BC, Bakshi R. Whole-brain atrophy assessed by proportional- versus registration-based pipelines from 3T MRI in multiple sclerosis. Brain Behav. 2018 Aug;8(8):e01068. doi: 10.1002/brb3.1068. Epub 2018 Jul 18. PMID: 30019857 138. Khalid F, Healy BC, Dupuy SL, Chu R, Chit nis T, Bakshi R, Houtchens M. Quantitative MRI analysis of cerebral lesions and atrophy in post -partum patients with multiple sclerosis. J Neurol Sci. 2018 Sep 15;392:94-99. doi: 10.1016/j.jns.2018.06.025. Epub 2018 Jun 30. PMID: 30031994 22 139. Campbell KA, Healy BC, Celano CM, Albanese A, Millstein RA, Huffman JC. Predictors of completion of a psychological-behavioral intervention in acute coronary syndrome patients. J Psychosom Res. 2018 Sep;112:9-12. doi: 10.1016/j.jpsychores.2018.06.006. Epub 2018 Jun 13. PMID: 30097141 140. Regev K, Healy BC, Paul A, Diaz-Cruz C, Mazzola MA, Raheja R, Glanz BI, Kivisäkk P, Chitnis T, Jagodic M, Piehl F, Olsson T, Khademi M, Hauser S, Oksenberg J, Khoury SJ, Weiner HL, Gandhi R. Identification of MS-specific serum miRNAs in an international multicenter study. Neurol Neuroimmunol Neuroinflamm. 2018 Aug 20;5(5):e491. doi: 10.1212/NXI.0000000000000491. eCollection 2018 Sep. PMID: 30175165 141. Dastagir A, Healy BC, Chua AS, Chitnis T, Weiner HL, Bakshi R, Tauhid S. Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis. eNeurologicalSci. 2018 Jul 4;12:42-46. doi: 10.1016/j.ensci.2018.07.002. eCollection 2018 Sep. 142. Healy BC, Glanz BI, Zurawski JD, Mazzola M, Chit nis T, Weiner HL. Long-term follow- up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate. J Neurol Sci. 2018 Nov 15;394:127-131. doi: 10.1016/j.jns.2018.09.020. Epub 2018 Sep 17. PMID: 30248571 143. Healy BC, Zurawski J, Gonzalez CT, Chitnis T, Weiner HL, Glanz BI. Assessment of computer adaptive testing version of the Neuro -QOL for people with multiple sclerosis. Mult Scler. 2018 Nov 1:1352458518810159. doi: 10.1177/1352458518810159. PMID: 30381985 144. Raheja R, Regev K, Healy BC. In response to: Study of serum microRNA expression in amyotrophic lateral sclerosis patients: The challenge of selecting suitable int ernal control for normalization. Muscle Nerve. 2018 Nov 1. doi: 10.1002/mus.26369. [Epub ahead of print] PMID: 30383297 145. Chu R, Kim G, Tauhid S, Khalid F, Healy BC, Bakshi R. Whole brain and deep gray matter atrophy detection over 5 years with 3T MRI in mu ltiple sclerosis using a variety of automated segmentation pipelines. PLoS One. 2018 Nov 8;13(11):e0206939. doi: 10.1371/journal.pone.0206939. eCollection 2018. PMID: 30408094 146. Huffman JC, Legler S, Millstein RA, Gomez Bernal F, Celano CM, Chung WJ, Healy BC. Does timeframe adjustment of the Life Orientation Test-Revised assess optimism as a state? J Pos Psychol 2018, in press. 147. Hernán MA, Hsu J, Healy B. Data science is science’s second chance to get causal inference right: A classification of data science tasks (April 2018). arXiv:1804.10846 148. Fakih R, Diaz-Cruz C, Chua AS, Gonzalez C, Healy BC, Sattarnezhad N, Glanz BI, Weiner HL, Chitnis T. Food allergies are associated with increased disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2018 Dec 18. pii: jnnp-2018-319301. doi: 10.1136/jnnp- 2018-319301. [Epub ahead of print] PMID: 30563943 149. Chitnis T, Gonzalez C, Healy BC, Saxena S, Rosso M, Barro C, Michalak Z, Paul A, 23 Kivisakk P, Diaz-Cruz C, Sattarnezhad N, Pierre IV, Glanz BI, Tomic D, Kropshofer H, Häring D, Leppert D, Kappos L, Bakshi R, Weiner HL, Kuhle J. Neurofilament light chain serum levels correlate with 10-year MRI out comes in multiple sclerosis. Ann Clin Transl Neurol. 2018 Oct 16;5(12):1478-1491. doi: 10.1002/acn3.638. eCollection 2018 Dec. PMID: 30564615 150. Hemond CC, Glanz BI, Bakshi R, Chitnis T, Healy BC. The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratio s are independently associated with neurological disability and brain atrophy in multiple sclerosis. BMC Neurol. 2019 Feb 12;19(1):23. doi: 10.1186/s12883-019-1245- 2. PMID: 30755165 151. Zurawski J, Glanz BI, Chua A, Lokhande H, Rotstein D, Weiner H, Engler D, Chitnis T, Healy BC. Time between expanded disability status scale (EDSS) scores. Mult Scler Relat Disord. 2019 Feb 5;30:98-103. doi: 10.1016/j.msard.2019.02.007. PMID: 30763908 152. Hemond CC, Healy BC, Tauhid S, Mazzola MA, Quintana FJ, Gandhi R, Weiner HL, Bakshi R. MRI phenotypes in MS: Longitudinal changes and miRNA signatures. Neurol Neuroimmunol Neuroinflamm. 2019 Feb 14;6(2):e530. doi: 10.1212/NXI.0000000000000530. eCollection 2019 Mar. PMID: 30800720 153. Rosso M, Kimbrough DJ, Gonzalez CT, Glanz BI, Healy BC, Rocca MA, Filippi M, Weiner H, Chitnis T. Cross-sectional study of smoking exposure: no differential effect on OCT metrics in a cohort of MS patients. Mult Scler J Exp Transl Clin. 2019 Feb 25;5(1):2055217319828400. doi: 10.1177/2055217319828400. eCollection 2019 Jan-Mar. PMID: 30828461 154. Huffman JC, Feig EH, Millstein RA, Freedman M, Healy BC, Chung WJ, Amonoo HL, Malloy L, Slawsby E, Ja nuzzi JL, Celano CM. Usefulness of a Positive Psychology-Motivational Interviewing Intervention to Promote Positive Affect and Physical Activity After an Acute Coronary Syndrome. Am J Cardiol. 2019 Jun 15;123(12):1906-1914. doi: 10.1016/j.amjcard.2019.03.023. Epub 2019 Mar 19. PMID: 30979409 155. Zurawski J, Glanz BI, Healy BC, Tauhid S, Khalid F, Chitnis T, Weiner HL, Bakshi R. The impact of cervical spinal cord atrophy on quality of life in multiple sclero sis. J Neurol Sci. 2019 Apr 18;403:38-43. doi: 10.1016/j.jns.2019.04.023. [Epub ahead of print] PMID: 31207364 156. Legler SR, Beale EE, Cela no CM, Beach SR, Healy BC, Huffman JC. State Gratitude for One's Life and Health after an Acute Coronary Syndrome: Prospective Associations with Physical Activity, Medical Adherence and Re-hospitalizations. J Posit Psychol. 2019;14(3):283-291. doi: 10.1080/17439760.2017.1414295. Epub 2018 Jan 4. PMID: 31217805 157. Barker L, Healy BC, Chan E, Leclaire K, Glanz BI. A Pilot Study to Assess At-Home Speed of Processing Training for Individuals with Multiple Sclerosis. Mult Scler Int. 2019 Jun 3;2019:3584259. doi: 10.1155/2019/3584259. eCollection 2019. PMID: 31275652 158. Duque L, Brown L, Celano CM, Healy B, Huffman JC. Is it better to cultivate positive affect or optimism? Pred icting improvements in medical adherence following a positive psychology intervention in patients with acute coronary syndrome. Gen Hosp Psychiatry. 2019 Nov - Dec;61:125-129. doi: 10.1016/j.genhosppsych.2019.06.001. Epub 2019 Jun 4. PMID: 24 31280918 159. Nikrahan GR, Eshaghi L, Massey CN, Hemmat A, Amonoo HL, Healy B, Huffman JC. Randomized controlled trial of a well-being intervention in cardiac patients. Gen Hosp Psychiatry. 2019 Nov - Dec;61:116-124. doi: 10.1016/j.genhosppsych.2019.06.005. Epub 2019 Jun 14. PMID: 31285062 160. Yano H, Gonzalez C, Healy BC, Glanz BI, Weiner HL, Chitnis T. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes. Mult Scler Relat D isord. 2019 Oct;35:119-127. doi: 10.1016/j.msard.2019.07.021. Epub 2019 Jul 25. PMID: 31374460 161. Palotai M, Cavallari M, Koubiyr I, Morales Pinzon A, Nazeri A, Healy BC, Glanz B, Weiner HL, Chitnis T, Guttmann CR. Microstructural fronto -striatal and temporo-insular alterations are associated wit h fatigue in patients with multiple sclerosis independent of white matter lesion load and depression. Mult Scler. 2019 Aug 16:1352458519869185. doi: 10.1177/1352458519869185. [Epub ahead of print] PMID: 31418637 162. Bjornevik K, Munger KL, Cortese M, Barro C, Healy BC, Niebuhr DW, Scher AI, Kuhle J, Ascherio A. Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis. JAMA Neurol. 2019 Sep 13. doi: 10.1001/jamaneurol.2019.3238. [Epub ahead of print] PMID: 31515562 163. Keyhanian K, Saxena S, Gombolay G, Healy BC, Misra M, Chitnis T. Adipokines are associated with pediatric multiple sclerosis risk and course. Mult Scler Relat Disord. 2019 Sep 5;36:101384. doi: 10.1016/j.msard.2019.101384. [Epub ahead of print] PMID: 31550559 164. Huffman JC, Millstein RA, Celano CM, Healy BC, Park ER, Collins LM. Developing a Psychological-Behavioral Intervention in Cardiac Patients Using the Multiphase Optimization Strategy: Lessons Learned From the Field. Ann Behav Med. 2019 Oct 5. pii: kaz035. doi: 10.1093/abm/kaz035. [Epub ahead of print] PMID: 31586194 165. Palotai M, Nazeri A, Cavallari M, Healy BC, Glanz B, Gold SM, Weiner HL, Chitnis T, Guttmann CRG. History of fatigue in multiple sclerosis is associated with grey matter atrophy. Sci Rep. 2019 Oct 14;9(1):14781. doi: 10.1038/s41598-019-51110-2. PMID: 31611598 166. Zurawski J, Tauhid S, Chu R, Khalid F, Healy BC, Weiner HL, Bakshi R. 7T MRI cerebral leptomeningeal enhancement is common in relapsing -remitting multiple sclerosis and is associated with cortical and thalamic lesions. Mult Scler. 2019 Nov 12:1352458519885106. doi: 10.1177/1352458519885106. [Epub ahead of print] PMID: 31714181 167. Smith DM, Duque L, Huffman JC, Healy BC, Celano CM. Text Message Interventions for Physical Activity: A Systematic Review and Meta-Analysis. Am J Prev Med. 2019 Nov 20. pii: S0749-3797(19)30367-8. doi: 10.1016/j.amepre.2019.08.014. [Epub ahead of print] Review. PMID: 31759805 168. Chitnis T, Glanz BI, Gonzalez C, Healy BC, Saraceno TJ, Sattarnezhad N, Diaz-Cruz C, Polgar-Turcsanyi M, Tummala S, Bakshi R, Bajaj VS, Ben-Shimol D, Bikhchandani N, Blocker 25 AW, Burkart J, Cendrillon R, Cusack MP, Demiralp E, Jooste SK, Kharbouch A, Lee AA, Lehár J, Liu M, Mahadevan S, Murphy M, Norton LC, Parlikar TA, Pathak A, Shoeb A, Soderberg E, Stephens P, Stoertz AH, Thng F, Tumkur K, Wang H, Rho des J, Rudick RA, Ransohoff RM, Phillips GA, Bruzik E, Marks WJ, Weiner HL, Snyder TM. Quantifying neurolo gic disease using biosensor measurements in-clinic and in free-living settings in multiple sclerosis. NPJ Digit Med. 2019 Dec 11;2:123. doi: 10.1038/s41746-019-0197-7. eCollection 2019. PMID: 31840094 169. Palotai M, Cavallari M, Healy BC, Guttmann CR. A novel classification of fatigue in multiple sclerosis based on longitudinal assessments. Mult Scler. 2020 Jan 23:1352458519898112. doi: 10.1177/1352458519898112. PMID: 31971067 170. Bakshi R, Healy BC, Dupuy SL, Kirkish G, Khalid F, Gundel T, Asteggiano C, Yousuf F, Alexander A, Hauser SL, Weiner HL, Henry RG; SUMMIT consortium. Brain MRI Predicts Worsening Multiple Sclerosis Disability over 5 Years in the SUMMI T Study. J Neuroimaging. 2020 Mar;30(2):212-218. doi: 10.1111/jon.12688. PMID: 31994814 171. Glanz BI, Zurawski J, Gonzalez CT, Shamah R, Ratajska A, Chitnis T, Weiner HL, Healy BC. Comparison of health-related quality of life across treatment groups in individuals with multiple sclerosis. Mult Scler Relat Disord. 2020 Jan 11;40:101944. doi: 10.1016/j.msard.2020.101944. PMID: 32007653 172. Zurawski J, Healy BC, Ratajska A, Barker L, Glanz BI, Houtchens M. Identification of a predominant cognitive phenotype in patie nts with multiple sclerosis. Eur J Neurol. 2020 Feb 21. doi: 10.1111/ene.14186. PMID: 32080929 173. Dickerman BA, Ebot EM, Healy BC, Wilson KM, Eliassen AH, Ascherio A, Pernar CH, Zeleznik OA, Vander Heiden MG, Clish CB, Giovannucci E, Mucci LA. A Metabolomics Analysis of Adiposity and Advanced Prostate Cancer Risk in the Health Professionals Follow -Up Study. Metabolites. 2020 Mar 10;10(3). pii: E99. doi: 10.3390/metabo10030099. PMID: 32164144 174. Varkaris A, Xu W, Davis RB, Healy B, McDermott DF. Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients With Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2019 Dec 5. pii: S1558-7673(19)30367-2. doi: 10.1016/j.clgc.2019.11.016. PMID: 32144046 175. Healy BC, Barker L, Bakshi R, Benedict RHB, Gonzalez CT, Chitnis T, Weiner HL, Glanz BI. Trajectories of Symbol Digit Modalities Test performance in individuals with multiple sclerosis. Mult Scler. 2020 Mar 31:1352458520913439. doi: 10.1177/1352458520913439. PMID: 32228283 176. Molsberry S, Bjornevik K, Hughes KC, Zhang ZJ, Jeanfavre S, Clish C, Healy B, Schwarzschild M, Ascherio A. Plasma Metabolomic Markers of Insulin Resistance and Diabetes and Rate of Incident Parkinson's Disease. J Parkinsons Dis. 2020 Mar 31. doi: 10.3233/JPD - 191896. PMID: 32250318 Professional educational materials or reports, in print or other media 26 1. Healy BC, Liguori M. “Predicting clinical course.” Multiple Sclerosis: Diagnosis and Therapy, Howard L. Weiner, James M. Stank iewicz, ed., Wiley-Blackwell, Oxford, UK: 2012. 2. Szymonifka J, Healy BC. “Basic statistics.” MGH Cardio logy Board Review, Hanna K. Gaggin, James L. Januzzi, ed., Springer, London, United Kingdom: 2013. We b tutorials for statistical a nalysis and lecture slides for introductory biostatistics course (http://hedwig.mgh.harvard.edu/biostatistics/bhealy/biostatistics_links) These tutorials are intended for students of my introductory statistics courses at MGH to demonstrate how to comp lete statistical analyses in Microsoft Excel and STATA. Thesis Healy BC. Combining retrospective and prospective data in characterizing accumulation of antiviral drug resistance mutations [dissertation]. Boston (MA): Harvard University; 2007. Narrative Report (limit to 500 words) I am a biostatistician who works on modeling disease progression in multiple sclerosis (MS) and teaches biostatistics to a wide range of audiences. I have written papers on statistical issues in MS, and I have provided statistical analysis for many other papers related to MS. In addition, I am the biostatistician for the Cardiac Psychiatry Research Program (CPRP) at Massachusetts General Hospital (MGH). For t he CPRP, I help design clinical studies, and I analyze and interpret the results from these studies. In addition to my research, I have developed and taught introductory biostatistics course to many groups throughout the hospital and university, including developing the Harvard Catalyst Certificate in Applied Biostatistics. My time is divided approximately 60/40 between research/teaching. In terms of research, I have been the primary biostatistician for the Partners MS Center and the comprehensive longitud inal investigation of multiple sc lerosis at Brigham and Women’s Hospital (CLIMB) for the past twelve years. My contributions have led to over 100 published papers on MS, including several papers that I have written regarding statistical methods or epidemio logical issues in MS. My papers have compared treatment regimens to determine how to treat patients and identified alternative methods for the analysis of disease progression. My collaborative work has addressed immunologic, imaging and cognitive aspects of the disease. My present MS research focuses on treatment decisions in MS. In addition, I have started (with Dr. Bonnie Glanz) the first patient engagement panel for MS at BWH. Beyond MS, I am the biostatistician for the CPRP, which aims to find interventions to improve outcomes in card iac patients using collaborative care and psychosocial interventions. In terms of teaching and education, I have designed and delivered many courses on introductory biostatistics for researchers across Harvard University and the affiliated hospitals. I have developed the Certificate in Applied Biostatistics from Harvard Catalyst, whic h is a 35-week program that introduces researchers to the most commonly used approaches in medical statistics. Over the last 7 years, this program has educated over 1200 students, and the number of students interested in the program continues to grow. I helped develop the curriculum and delivered lectures for t he clinical scholar research training (CSRT) and global clinical scholar research t raining (GCSRT) programs, and I a m the Director of Clinical Research Methods for the Harvard Medical School Global and Continuing Education department. I also co -direct (with Dr. Miguel Hernan) the clinical data science series for the Masters of Medical S cience and Clinical Investigation (MMSCI) at HMS, and I teach the biostatistics component of the first course in the Masters of Public Health in Epidemiology, which is the first blended degree program at Harvard University. All of these programs receive extremely high scores for teaching. I have combined excellent research with a commitment to teaching over my time at Harvard. My research 27 has improved the clinical understanding of MS and integrated state of the art statistical techniques into MS research. My teaching has introduced many researchers to statistical thinking, which I believe has improved the quality of research at the hospital. lTown of Reading I 16 Lowell Street I neading MA 01867 I Town Clerk fax: 781-942-90707BL-942-9050 website: www.readingma,gov Aoolication for Apfointment to Boards, Committees and Commissions Name:Q,.ho.) A (First) lo5 CoAddress:'€qd,rn Phone (Work):N/L Phone (Cell):lgt ^L+g - l03r Which number should be listed? Cetl Occupation: E-mail address: Place a number next to your preferred position(s) (up to four choices) with number 1 being your first priority. (Please attach a resume if available) Number of years in Reading: Ak Phone (Home): N - _ Animal Control Appeals Committee _ Board of AssessorsI Board of Health _ Bylaw Committee _ Climate Advisory Committee _ Human Relations Advisory Committee _ RCTV Board of Directors _ Retirement Board - Community Planning and Development Commission _ Conservation Commission_ Constables _ Council on Aging _ Audit Committee _ Board of Cemetery Trustees _ Board of Registrars - Celebration Trust Committee_ Commissioners of Trust Funds _ Permanent Building Committee _ Recreation Committee _ RMLD Citizen Advisory Board - Cultural Council - Custodian of Soldier and Sailor Graves_ Finance Committee _ Historic District Commission_ Historical Commission _ Housing Authority _ Town Forest Committee _ Trails Committee _ Veterans Memorial Trust Fund Committee _ Zoning Board of Appeals Other Please outline relevant experience for the position(s) sought: uvtzd tt+t- qtrttt Curriculum Vitae Richard Lopez, MD 105 Red Gate Lane Reading, MA 01867 rlopez430@comcast.net Cell 781-248-1035 Executive Summary Physician Executive with 35+ years of extensive experience in leadership roles. Proven track record of translatin g vision into results. Collaborative, consensus-building style with strong goal-oriented focus. Diversified management portfolio including clinical operations, disease management, clinical information systems, pay for performance contracting, utilization /medical management, and physician supervision. Excellent communication and writing skills. Experienced in staff management, operations, financial management, and analytical skills. Professional Background Retired July 2018 Senior Vice President, Population Health 2016 to 2018 Chief Medical Officer, VNA Care Network Atrius Health Responsible for the population health resources available to manage population health in the newly integrated Atrius Health medical group consisting of 850 physicians and 700,000 patients. This includes the internal medicine, family practice, pediatric, and behavioral health practices and care management programs such as analytics and reporting, clinical informatics, case management, chronic disease management, clinical pharmacy, and home/skilled nursing facility programs. Ongoing accountability for hospital and health plan strategy/contracting/relationships. As Chief Medical Officer of Massachusetts’ largest non -hospital based VNA, responsible for clinical program integration and collaboration between the medical group and the VNA, physician advisory roles across a spectrum of functional areas, and support to governmental advocacy, development, and contracting. Chief Physician Executive/Chief Medical Officer 2009 to 2015 Atrius Health Responsible for the corporate resources supporting Atrius Health’s six medical groups consisting of 1000 physicians at 40 locations in Eastern and Central Massachusetts caring for close to one million patients; areas of responsibility includes clinical informatics/EMR, data analytics, quality and safety, risk management, hospital and health plan relationships, medical management, disease management, clinical pharmacy, health plan delegation, and ACO program development. Vice President of Clinical Programs 2007 to 2009 Harvard Vanguard Medical Associates Interim Chief Medical Officer 2005 to 2007 HealthOne Care System Boston, MA Deputy Medical Director 2001 to 2007 Harvard Vanguard Medical Associates Boston, MA Directly responsible for the management of several medical management programs including case management, hospitalist, extended care facility, and high-risk patient management programs with total operating budget of $11M. Provides senior physician oversight of the in -house clinical pharmacy program and P&T Committee. Responsible for clinical relationships with four major payors in the Boston area including negotiating pay for performance goals and delegated medical management. • Implemented a central outreach program for HEDIS related metrics using an electronic medical record database that resulted in 5-15% increases in multiple HEDIS scores over a 3-year period. • Negotiated pay for performance goals with major health plans with consistent achievement of goals worth $2 - 4M annually • Led two separate efforts to direct inpatient volume from a tertiary hospital to a secondary-care hospital with minimal disruption in clinical operations and substantial financial savings • Designed and implemented new medical programs focused on the management of chronic conditions and homebound patients. Associate Medical Director 1997 to 2001 Harvard Vanguard Medical Associates Boston, MA Directly responsible for case management and hospitalist programs in addition to ancillary programs including laboratory, medical records, and pharmacy. Responsible for the development of medical/utilization management programs and initiatives focused on management of medical expense. Senior physician executive responsible for the implementation of a new electronic medical record. • Implemented a new electronic medical record (EpicCare, Epic Systems, Madison, WI) at 14 Harvard Vanguard practice sites that transformed the practice to an entirely paperless environment. Quality of the implementation was recognized by the Computer -based Patient Record Institute with the national Nicholas E. Davies Award for excellence in implementation of an EMR in November 2000. • Envisioned, design, developed and implemented a Clinical Initiatives Program which provided a structure for the creation of new disease management programs. The program included a process for the selection of id eas, funding support for design and implementation, and an approach to evaluation and recognition. The effort resulted in the creation of several new programs - Palliative Care, Chronic Kidney Disease, and Adult COPD - and supported the growth of existing programs such as Congestive Heart Failure and End-Stage Renal Programs. Piloted and launched the implementation of the Anticoagulation Management Program that now services 4500 patients. Demonstrated reduction in medical costs as a result of these programs. • Responsible for the creation of a successful clinical pharmacy program to help manage pharmaceutical costs • Implemented an open referral program across all specialties, one of the first programs of its kind nationally in staff model HMO’s. Health Center Director 1990 to 1997 Harvard Community Health Plan/Harvard Pilgrim Health Care Medford/Somerville, MA Overall responsibility as the medical director in a staff model HMO for the Medford clinic of Harvard Community Health Plan for 7 years and both the Medford and Somerville clinics from 1993-1997. In this role, responsible for 200-300 staff at each site with full budget responsibility for $10-18M. Direct responsibility for physician management, clinical quality, utilization management, and program development. • Lead role in opening new internal medicine practice a Somerville; led the development of regional urgent care and orthopedic programs at Somerville • Chaired a multidisciplinary committee at the divisional level to develop utilization reports to the physician level across multiple sites and specialties Additional Experience Chief of Internal Medicine 1985 to 1990 Harvard Community Health Plan Medford, MA Board-Certified Primary Care Internist 1982 to 2018 Harvard Community/Harvard Pilgrim/Harvard Vanguard/Atrius Health Medford, MA Senior Assistant Surgeon 1980 to 1982 U.S. P.H.S. Commissioned Corps Kenova, WV National Health Services Corps Education and Medical Training St Elizabeth's Hospital 1982 Resident in Medicine Brighton, MA St Elizabeth's Hospital Boston, MA 1978 Intern in Medicine Brighton, MA Doctor of Medicine 1977 Boston University School of Medicine Boston, MA B.A., summa cum laude 1977 Boston University Affiliations American Medical Association 1978 to 1982 Member, American College of Physicians 1980 to present Member, American College of Physician Executives 1988 to present Massachusetts Medical Society 2006 to present Academic Appointments Clinical Instructor in Medicine 1980-1982 Marshall University School of Medicine Huntington, West Virginia Clinical Instructor in Medicine 1982- 2015 Harvard Medical School Boston, MA Hospital Appointments Harvard Community Health Plan Hospital 1982-1986 Malden Hospital 1982-1998 Lawrence Memorial Hospital 1982-2000 Beth Israel Hospital 1982-2001 Brigham Women’s Hospital 1986 - 2013 Faulkner Hospital 2001- 2010 Mount Auburn Hospital 2008 - present Licensure and Certification Massachusetts Board of Registration in Medicine 1979 - present Medical License, West Virginia 1977 to 1979 Board Certification, Amer ican Board of Internal Medicine 1980 Honors and Awards Phi Beta Kappa, 1977 Joseph L. Dorsey Award, Harvard Community Health Plan, 1985 Diamond Award, Harvard Community Health Plan, 1994 Received on behalf of Harvard Vanguard the Nicholas E. Davies Award, Computer-based Patient Record Institute 2000 Partners in Excellence Award, Partn ers Health Care, 2002 Lifetime Achievement Award, Harvard Vanguard Medical Associates 2008 Becker Healthcare 2014 Leadership Award 2014 Lifetime Achievement Award, Massachusetts Medical Society 2019 Other Professional Activities Member, Massachusetts Board of Registration in Pharmacy 2019- Member of Board Subcommittee: Atrius Health System of Care Committee 2019- Member, Mass Hospital Association Physician Hospital Integration Council (Vice Chair 2016; Chair 2017) 2015- 2018 Member, Statewide Quality Advisory Committee 2012- 2018 Chair, New England Comparative Effectiveness Public Advisory Council 2011-2013 Board Trustee, Mass Coalition for the Prevention of Medical Errors 2010-2013 Board Trustee, Atrius Health 2009-2015 Board Trustee, Atrius Health Foundation 2009-2015 Board Trustee, Risk Management Foundation 2009-2018 Operations Committee, CRICO/RMF (Chair 2015 – 2018) 2009- 2018 Underwriting Committee, CRICO/RMF 2014- 2018 Member, Expert Panel on Performance Measurement, Health Care Quality and Cost Council 2009-2012 Mass Medical Society Committee on Quality of Medical Practice (Vice Chair 2015 – 2019) 2009- Massachusetts Medical Society Task Force on Medical Costs 2007-2018 BCBSMA Eastern Massachusetts Healthcare Initiative, Performance Measurement and Reporting Workgroup 2006 MD-MBA Program, Guest Lecturer, Tufts University School of Medicine 2000-2006 Neighborhood Health Plan Patien t Care Assessment Committee 2005-2011 Blue Cross/Blue Shield Coronary Artery Disease Advisory Committee 2004-2012 Blue Cross/Blue Shield Physician Advisory Committee 2004-2015 Brigham Women’s Hospital Medical Staff Credentialing Committee 2004-2013 Tufts Quality Council 2001-2015 Tufts Central Physicians Committee 2001-2016 HPHC Integrated Delivery Network Physicians Committee 2000-2018 Publications and Presentations Panel Discussion: “Advancing Health Plan Partnerships”, American Medical Group Association, February 11, 2020. Panel Discussion: “Building Physician Hospital Alignment in a Value Driven World”, Massachusetts Hospital Association Annual Meeting, June 7, 2018, Danvers, MA Panel Discussion: “Optimizing Outcomes: the Promise of Population Health Strategies”, Massachusetts Hospital Association Annual Meeting, June 7, 2018, Danvers, MA Webinar Presentation: “ NextGen ACO Strategies to Reduce Avoidable Emergency Room Utilization”, Learning Systems for Accountable Care Organizations, NextGen ACO Shared Learning Webinar, June 7, 2018 Webinar Presentation: “Levers of Successful ACO’s”, Health Care Transformation Task Force, December 5, 2017. Presentation and Panel Discussion: “Care Management Convergence: A Perspective”, Chilmark Convergence 2017 Conference, Boston, MA October 5, 2017. Presentation: “Translating Value Based Payments into Clinical and Operational Decision -Making”, Connecticut Practice Transformation Summit, Hartford, CT September 15, 2017 Panel Discussion: “Provider Responses to Change”, MACRA, me! Knitting Together Market Forces and Provider Responses”, HFMA, Norwood, MA March 10, 2017 Presentation: “Medical Neighborhoods: Population Health Partnerships Across the Continuum”, Remington’s 15th Annual think Tank Summit, San Diego, CA March 5, 2017 Panel Discussion: “The Evolution of Health Care Delivery”, Navigating the Total Health Revolution, New England Employee Benefits Council, Newton, MA, June 10, 2016 “Advanced care planning plays essential role in a truly patient -centered healthcare system”, Modern Healthcare, May 2, 2016 Panel Discussion: “Bottom Line Battles: From Generics to Personalized Medicine” Healthcare at the Intersection of Cost and Innovation, MHA, Framingham, MA January 29, 2016 Presentation: “Atrius Health: The Quality and Safety Journey Using EpicCare (1997-2015), Partners Quality and Safety Retreat, Boston, MA December 8, 2015 Presentation: “Atrius Health’s Population Health Strategy: ACO as the Platform”, Webinar, June 18, 2015 Presentation: “New Models of Care and Approaches to Payment”, Alliance for Home Health Quality and Innovation, Washington DC September 30, 2014 Presentation: “How ACO’s Are Thinking of Home Care: the Atrius Health Experience”, NE Home Health Care Conference, Boston, MA May 29, 2014 Presentation: “Atrius Health Initiative Relative to Transparency in Cost” Mass Health Data Consortium, Waltham, MA April 10, 2014 Presentation: “Atrius Health: Leveraging Clinical Pharmacy for Quality and Cost Improvement” Mass Hospit al Association, Burlington, MA February 27, 2014. Panel Discussion: “Pioneer Program: Who Took the Leap and Why” 2012: The End of the World or the Beginning of a New World in Managed Care” sponsored by the Health Finance Management Association, Westborough, MA June 8, 2012. Panel Discussion: “Using HIE to Improve the Quality of Care” HIE: The Key to Integration and Accountability sponsored by the Mass Health Data Consortium, Norwood, MA June 8, 2012. Panel Discussion and Moderator: “Health Care Payment Reform and Physician Behavior” Avoiding Avoidable Care Conference sponsored by the Lown Foundation, Cambridge, MA April 26, 2012. Presentation: “Atrius Health Pioneer ACO Initiative: Implications for Post Acute Care” Reliant Medical Group Division of Geriatrics Annual Conference, Boylston, MA April 4, 2012 Panel Presentation and Discussion: “Health Care Reform: Moving from Theory to Action” Massachusetts Chapter of the American College of Healthcare Executives, Boston, MA March 1, 2012 Panel Discussion: “Crossing Boundaries in Drug Development: Perspectives on Drug Pricing and Rei mbursement” Healthcare Businesswomen’s Association, Cambridge, MA October 12, 2011. Op-Ed: “A public voice on what works well in health care”, Steve Pearson and Richard Lopez, Boston Globe, October 14, 2011. McDermott, Will, and Emory National Webinar: “Best Practices, Evidence Based Care, and the Evolution Clinical Care in the ACO Era” March 2011 Panel Discussion: “Health Reform Strategies: ACO’s, Evolving Payment Systems, and the Role of Aging Services” Lifetime Care Solutions, In c Annual Conference, Beverly, MA November 2010 Presentation: “Turning On Referral Management” CRICO/RMF 2009 Annual Patient Safety Summit, June 16, 2009, Boston, MA Presentation: “Quality as a Business Strategy: the Harvard Vanguard Medical Associates Experience” Massachusetts League of Community Health Centers, February 10, 2009, Boston, MA Panel Discussion: “Best Practices and Generating Support for Quality Initiatives” State of Our Health, A Massachusetts Leadership Forum on Healthcare Quality Measurement and Improvement, November 2003, Boston, MA Panel Discussion: “Delivering Biomedical Breakthroughs to Patients” Massachusetts Biotechnology Council Annual Meeting and Trade Exposition, April 2002. "Quality Enhancements via Electronic Medical Records." Forum. Risk Management Foundation of the Harvard Medical Institutions, February 2000, pp 14-16 Presentation : “Total Quality Management: What It Means for the HMO Clinician” GHAA Group Health Institute, June 1992, Minneapolis, MN